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Abstract
The biomarker discovery pipeline is a multi-step endeavor to identify potential
diagnostic or prognostic markers of a disease. Although the advent of modern
mass spectrometers has revolutionized the initial discovery phase, a significant
bottleneck still exists when validating discovered biomarkers. In this doctoral
research, I demonstrate that the discovery, verification and validation of
biomarkers can all be performed using mass spectrometry and apply the
biomarker pipeline to the context of clinical delirium.

First, a systematic review of recent literature provided a birds-eye view of
untargeted, discovery proteomic attempts for biomarkers of delirium in the
geriatric population. Here, a comprehensive search from five databases yielded
1172 publications, from which eight peer-reviewed studies met our defined
inclusion criteria. Despite the paucity of published studies that applied systemsbiology approaches for biomarker discovery on the subject, lessons learned and
insights from this review was instrumental in the study designing and proteomics
analyses of plasma sample in our cohort.

We then performed a targeted study on four biomarkers for their potential
mediation role in the occurrence of delirium after high-dose intra-operative
oxygen treatment. Although S100B calcium binding protein (S100B), gamma
enolase (ENO2), chitinase-3-like protein 1 (CHI3L1) and ubiquitin carboxyl-
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terminal hydrolase isozyme L1 (UCHL1) have well-documented associations with
delirium, we did not find any such associations in our cohort. Of note, this study
demonstrates that the use of targeted approaches for the purposes of biomarker
discovery, rather than an untargeted, systems-biology approach, is unavoidably
biased and may lead to misleading conclusions.

Lastly, we applied lessons learned and comprehensively profiled the plasma
samples of delirium cases and non-delirium cases, at both pre- and post-surgical
timepoints. We found 16 biomarkers as signatures of cardiopulmonary bypass,
and 11 as potential diagnostic candidates of delirium (AuROC = 93%). We
validated the discovered biomarkers on the same mass spectrometry platform
without the use of traditional affinity-based validation methods. Our discovery of
novel biomarkers with no know association with delirium such as serum amyloid
A1 (SAA1) and A2 (SAA2), pepsinogen A3 (PEPA3) and cathepsin B (CATB)
shed new lights on possible neuronal pathomechanisms.
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Chapter One: Introduction

Biological Mass Spectrometry for Clinical Biomarker Discovery
The use of diagnostic biomarkers is central to patient care. Biomarkers are
useful, not only for the early detection of pathological changes before overt
clinical manifestations, but also for monitoring treatment and for predicting
outcomes. Within the omics spectrum, proteins are more proximal reporters of
diseases than genes and transcripts, and most diseases manifest at the level of
protein activity. It is therefore not surprising that protein-based biomarkers form a
substantial proportion of laboratory tests requested in clinical practice. Despite
their substantial role in diagnostics, the last few years have seen a significant
decline in the number of protein biomarkers approved by the FDA for clinical
use.[9-11]
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Several reasons have been suggested for this down-trending observation in
protein biomarker discovery. Until recently, profiling biofluids for proteomic
signatures was mostly achieved using two-dimensional (2-DE) electrophoresis
beginning in the 70s.[12-14] Despite the many successes with 2-DE systems,[1519] the lack of reproducibility, the narrow dynamic range and inability to identify
low abundance and/or hydrophobic proteins, among other limitations,
underscored the need for high-resolution platforms. Liquid chromatography (LC)
equipped with mass spectrometry (MS) overcame some of these aforementioned
challenges and opened the gateway for the unbiased analyses and quantification
of proteins even in complex biological samples. The advent of modern mass
spectrometers, the availability of comprehensive protein sequence databases
and the introduction of new peptide labeling schemes has enhanced the
accuracy, sensitivity and multiplexing capabilities of mass spectrometers,
allowing for the comprehensive analyses and quantification of proteins from
multiple batches of samples at a time.

Notwithstanding the substantial progress in protein identification, a primary
bottleneck in the biomarker workflow is the failure to validate candidate
biomarkers. The use of traditional affinity-based methods to validate biomarkers
discovered by MS could delay biomarker translational research and FDA
approval by about a demi-decade.[20, 21] To accelerate the biomarker pipeline,
we must close the translational gap between the bench and the bedside. This
doctoral research contributes to the growing body of knowledge that biomarker
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discovery and subsequent antibody-free validation is achievable on the same MS
platform. Here, we applied MS-based discovery and validation pipeline to the
specific context of post-operative delirium, using systems-biology approaches.
Additionally, it is demonstrated that careful study designing, clarity regarding the
intended use of the biomarkers (for screening, diagnosis or prognosis), use of the
appropriate study population, choice of statistical tools and optimal sample
preparation all play important roles to ensuring successful biomarker discovery.

Background
The Need for Protein-based biomarkers
Biomarkers are, by definition, objectively measurable characteristics, useful in
evaluating a normal biological activity, a pathological process or a
pharmacological response to some therapeutic intervention.[22] Within the omics
spectrum, proteins are most preferred for diagnostic purposes. This is because
genomic sequencing provides unchanging probabilistic risk with limited
applicability beyond monogenic diseases such as hemophilia A, phenylketonuria
and osteogenesis imperfecta.[23-25] Diagnostic assays involving transcripts
(mRNA), on the other hand, has yet to gain widespread use in clinical
laboratories.[26] Although proteins and metabolites are the most proximal
reporters of diseases, proteins are unique in providing a functional snapshot of
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the body’s response to a disease process rather than metabolic products.
Furthermore, most diseases manifest at the level of protein activity, given their
central role in biosynthesis, signaling and structural stability of cell and
tissues.[27, 28] These make proteins ideal for diagnostics, for prediction and as
targets for intervention.[29] It is therefore not surprising that proteins (in particular
enzymes) are the most routinely requested biomarkers in clinical laboratories[30,
31].

The broader clinical significance of protein biomarkers is also evident in routine
laboratory medicine. For example, a positive post-urea breath test for 13CO2
molecules only suggests an H pylori infection. However, detecting a BCR-ABL
fusion protein is not only diagnostic of chronic myeloid leukemia (CML) but is
also the target for Imatinib therapy and for monitoring drug response. Where the
underlying pathophysiology is unknown, discovered biomarkers have been
instrumental in shedding new lights on the mechanistic underpinnings of the
clinical condition in question.[32-34]

Advances in measurement technology and the rising number of putative
biomarkers reported in recent literature raise expectations about the ideal
biomarker. Biomarkers are required to be more sensitive, reliable and accurate in
identifying cases and quantifying the extent of a pathological change.
Additionally, the ideal biomarker is expected (1) to detect an active pathological

4

change very early in the disease process, preferably before significant changes
occur; (2) to be easily accessible, i.e., assaying from peripheral blood is generally
preferred to taking an invasive biopsy unless it is absolutely necessary; (3) to be
analytically stable and correlate well with worsening disease severity; and lastly
(4) to be associated with a known disease mechanism.[22, 35]

Based on these characteristics, there is clearly a significant unmet clinical need,
yet the proportion of FDA-approved in vitro diagnostics which are protein-based
assays remains low (Figure 1.1). This unmet need for protein biomarkers is
further reflected in the widening gap between published literature on putative
biomarker candidates and the number of FDA-approved candidates for clinical
use.[20, 29, 36] Attempts to fill this gap has led many authors to reimagine the
biomarker discovery pipeline in terms of the choice of biological samples, the
appropriateness of the study population, analytical platforms for measurement
and existing approaches for clinical validation.

Ideal sample sources of biomarker discovery
Human biofluids are a rich media of diagnostic material, useful in the detection of
pathological processes. They reflect the overall physiological state of an
individual[37] or the disease state of a specific organ-tissue, which makes
biofluids the ideal sample for biomarker discovery. Relative to other biospecimen
such as tissues, the relative ease of accessibility of biofluids fulfils a major
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Figure 1. 1 FDA approved biomarker assays (2011 - 2021)
The number of in vitro diagnostic (IVD) tests approved by the FDA for
professional use or as over the counter diagnostic, grouped into non-protein and
protein-based biomarkers. Numbers include novel biomarkers as well as approvals
after expiration of original patent terms. The FDA considers biomarker assays as medical
devices and adhere to the same regulatory standards as other types of medical devices.
Data source: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfIVD/search.cfm
(last accessed: 05/25/2022)
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criterion of the ideal biomarker. Use of urinary albumin to evaluate the risk of
diabetic nephropathy and use of antemortem CSF tau protein to detect
Alzheimer-type neuropathologic changes in the brain are well-known examples of
the diagnostic potential of biofluids.[38, 39]. The proteome of human biofluids can
be broadly categorized into native proteins, tissue leakage and signaling
proteins.

This consistent compositional pattern is observed when comparing discovery
proteomic experiments performed on blood, tears, saliva, urine, cerebrospinal
and synovial fluids.[40-45]

Analytical challenges of the human plasma proteome
Of these biofluids, blood plasma/serum is the most complex by composition, and
remains the most difficult proteome to characterize.[40] Proteins in plasma (or
serum) represents about 20% of the entire human proteome. The wide dynamic
range of protein concentrations spans about 10 – 12 orders of magnitude.[40] In
addition, approximately 95% of the total protein mass in plasma (or serum) is
made up of the 12 most abundant proteins (Figure 1.2).[46, 47] Because plasma
(or serum) contains leakage proteins from many tissues in the body, this
compositional complexity poses significant analytical challenges, as signal from
the proteins of interest may be impaired by the dominance of albumin and other
7

Figure 1. 2 Composition of the Plasma Proteome by Protein Mass
Data source from Pietrowska, Wlosowicz [48]
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high-abundance proteins.[29, 40, 49] Furthermore, post-translational
modifications and degradation mechanism by native plasma proteases in the
background of lipids, salts and small molecule metabolites further reduce
analytical sensitivity, reproducibility and resolution in unpredictable ways.[48, 49]

To reduce sample complexity and enhance signal from the low-abundance
plasma proteome frequently requires additional experimental steps to remove the
dominating high-abundance proteins. Immunodepletion, affinity enrichment and
fractionation are common pre- and post-digestion options compatible with
shotgun proteomics, although blood-derived exosomes have recently been
explored.[50-53] By far, immunodepletion is the most commonly employed
sample purification strategy, and affinity enrichment is most useful for the
analysis of post-translational modifications.[54] It is worth noting that no one
single approach is better than the others, and substantial removal of the highabundance proteome may require more than one approach. Briefly, while
immunodepletion by dye affinity resins rely on the covalent binding between the
anionic anthraquinone dye to agarose beads to deplete albumin, immunoaffinity
columns purify samples by binding to mono- or polyclonal antibodies immobilized
on resin beads. The High Select Top14 Abundant Protein Depletion Mini Spin
Columns (Thermo) and the PierceTM Albumin Depletion Kit® (Thermo Fisher
Scientific) are notable commercial examples.

9

These additional experimental steps, however important they may be in
enhancing signal from the low-abundance proteome, are without limitations. A
major concern about their use is the non-specific removal of proteins other than
what was targeted. Because of the role of albumin in the active transport of many
other proteins, Liu, Zhao [55] observed a remarkable loss of target proteins after
albumin depletion. Furthermore, there is considerable degree of variation in the
efficacy of the depletion step.[56] Possible reasons for this observation may
include saturation of antibody binding sites and the relatively low sample capacity
of antibodies used.

Following digestion of intact plasma proteins, separation strategies to reduce
sample complexity is commonly achieved using electrophoresis or
chromatography. Here, separation is achieved according to size, hydrophobicity,
charge, isoelectric point or by affinity.[57] Post-digestion chromatographic
fractionation involves the interaction of peptides with a stationary phase (e.g.
reversed-phase [RP] materials) and a mobile phase gradient. Modification of
properties of the mobile phase, either by changing the organic modifier
concentration, pH or the salt content over time, allows for the differential elution
of peptides.[58, 59] Given the benefits of extensive fractionation in reducing the
dynamic range of the proteome being studied,[59-61] multidimensional strategies
that combines orthogonal separation properties are often employed. Such is the
approach of an in-house offline pentafluorophenyl (PFP)-RP chromatographic
strategy that is orthogonal to the online C18-based reversed-phase
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separation.[62] Our in-house method, comparable to more commonly used
approaches such as Hi-pH RP fractionation, requires fewer experimental steps,
and has been demonstrated to be time-efficient and compatible with chemicallylabeled peptide species.

The choice between plasma and serum remains a long-standing debate. After
centrifugation of an anticoagulant-treated blood to suspend cells and cellular
debris, the remaining liquid component of blood is plasma. Omitting the
anticoagulant step results in serum, and the subsequent centrifugation also
allows for the removal of the fibrin clots. This results in significant qualitative and
quantitative differences between plasma and serum.[63, 64] In fact, the
coagulation step results in a 3 – 4% lower protein concentration in serum relative
to plasma.[65, 66] It is recommended that the decision to use plasma or serum
be guided by the purpose for the sample draw. However, for the specific
purposes of biomarker discovery requiring the unbiased profiling of blood,
removal of clotting factors (as in the case of serum) may contribute to nonspecific removal of other proteins of interest that may be associated with the
clotting factors. This is also the recommendation by the Human Proteome
Organization (HUPO), with the additional reason of a lower degree of ex vivo
degradation during the coagulation step [67]

11

Mass spectrometry-based Biomarker Discovery
The biomarker discovery workflow is a series of preclinical experiments and
clinical studies that aim to discover, verify and validate potential biomarkers of
the clinical condition under investigation. Typically beginning with a small set of
patient samples (figure 1.3), discovery proteomic experiments are conducted to
generate the foundational hypotheses of the study. Here, samples are
comprehensively profiled for all identifiable proteins that may explain the
differences in the proteomic profiles of cases and controls. At this stage,
experiments are designed to report protein abundance in relative terms (e.g., log
fold change between cases and controls). Common options for relative
quantification in shotgun proteomics include isotopic labeling (e.g., using
intensities from tandem mass tags or isobaric tags for relative and absolute
quantification), non-isobaric tagging (e.g., amine-specific, stable-isotope-labeled
reagents) or label-free quantification (by peak area integration or spectral
counting).

With a putative list of thousands of candidate biomarkers at this stage, the
qualification phase ensures that the biomarker readout is independent of the
discovery measurement platform and ascertains that a relationship between
abundance and clinical outcome exists.[68] Often times, this step is buried in the
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Figure 1. 3 Schematic overview of the biomarker discovery workflow
Each step forward requires substantially higher number of patient samples while
focusing on a panel of very few proteins for clinical evaluation.
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verification phase if the measurement platform used for verification is orthogonal
to that used for the discovery. Biomarker verification then measures identified
biomarker candidates in a larger independent set of samples with the primary
aim of eliminating false discoveries.

To date, this phase remains the main bottleneck in the biomarker workflow.[30,
69, 70] This is because traditional affinity-based verification methods, notably
ELISA, have limited multiplexing capabilities and are not suited for the high
throughput setup that biomarker verification demands. Besides, measurements
by ELISA are semi-quantitative.[71] ELISA verification also requires candidate
biomarkers to be antigenic and often exhibit cross-reactivity.[72, 73] Where
commercial antibodies are unavailable, developing high-quality assays for the
many biomarkers needing verification can be time-consuming (about 1 – 2 years
per antibody) and may be cost-prohibitive (over USD 100, 000 per antibody).[7477]. As a result, many discovered biomarkers are never verified.[1, 78]
Notwithstanding these, verification by ELISA is advantageous for the ability to
identify proteins with the least false positive rate and measure concentrations of
analytes even in low abundance.[79]

Fundamental to the biomarker pipeline is the unequivocal identification and
characterization of candidate analytes from study samples. As this step sets the
stage for many downstream steps at both the discovery and validation phases,
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the degree of certainty required in protein identification places high demands on
the quantitative assays used. Common assay types employed in the biomarker
pipeline include immunohistochemistry[80], enzyme-linked immunosorbent
assays (ELISA), flow cytometry[81], mass spectrometry, and more recently,
proximity extension assays[82] and SomaScan[83].

Mass spectrometry and modern mass analyzers
Of these measurement platforms, mass spectrometry (MS) remains the gold
standard for bioanalytical applications.[84] MS is a high throughput analytical
platform with the requisite sensitivity, unprecedented selectivity and resolution to
identify analytes in complex biological samples. The high mass accuracy and
speed makes MS uniquely suited to quantify analytes, even at attomole
concentrations.[85] At its fundamental level, MS has three functional
components: (1) sample introduction, (2) ionization and (3) detection and mass
analyses. The most common method for sample introduction is by liquid
chromatography. In a typical proteomics setup, liquid chromatography coupled
online to tandem mass spectrometers (LC-MS/MS) detects the input sample
dissolved in the mobile phase and pumps eluents under very high pressures
through a densely packed column containing the stationary phase.
Chromatographic separation of sample at this point, typically orthogonal to
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separation methods described earlier, is based on differential affinity of input
material to the stationary phase.

After successful separation and elution from the column, the sample undergoes
ionization and subsequent introduction into the mass spectrometer for detection
according to their mass to charge (m/z) ratios. The time it takes from analytes’
contact with the column material to elution off the column is the chromatographic
retention time (RT). For peptides, two ionization techniques are most commonly
employed: the electrospray ionization (ESI) and the matrix assisted laser
desorption/ionization (MALDI). Of the two, soft ionization by ESI is achieved by
applying an electric field to the sample in the capillary column. This produces
charged droplets that form gaseous ions with very little fragmentation.[86]
MALDI, on the other hand, achieves ionization by using short laser pulses to heat
up an acidic matrix containing the sample.[87] For a LC-MS/MS setup, ESI is
typically coupled to ions traps,[88] preferably because of the ease of introducing
ionized samples from the columns into the mass spectrometer. Considerable
gains in protein identification can be attributed to improvements in ion
transmission, speed, mass accuracy, duty cycle and resolution in modern mass
analyzers. Time-of-flight, Orbitraps and ion-traps are common mass analyzers,
each with unique properties in terms of resolution, duty cycle and acquisition
speed, among others.[89-91] Specifically for proteomics, a number of hybrid
configurations exits, such as the linear ion trap-Orbitrap, that combines the
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strengths of two or more mass analyzers to increase their ability to analyze
samples in tandem, as briefly described below.

Generally, the first mas analyzer, MS1, separates ionized species by their mass
to charge (m/s) ratio. Ions at a given m/z ratio are then selected for further
fragmentation, either by collision-induced dissociation, photodissociation or ionmolecule reactions. Fragments ions introduced into the second round of mass
analysis, MS2, provide the sequence information that is searched against the
appropriate database to identify proteins in the sample. Figure 1.4 shows an
example of data acquired by LC-MS/MS analysis of a plasma sample. Many
search algorithms exist for the identification of peptides from their respective
tandem mass spectra, most common ones being SEQUEST, MASCOT,
Andromeda and COMET. While SEQUEST computes cross-correlation scores by
comparing the experimental spectra with theoretically derived equivalents,[92]
MASCOT employs a probabilistic scoring metric, the expectation value, that
ascertains the probability that the observed match between the experimental
spectra and the protein database is random.[93] Conveniently integrated into the
MaxQuant Environment, Andromeda uses a probability metric for scoring
peptide-spectrum matches (PSM)[94]. Last but not the least, COMET works
similarly to SEQUEST. It however implements a faster cross-correlation scoring
by avoiding the creation, storing and indexing of theoretical spectra.[95]
Competing technologies
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SomaScan (SomaLogic, Inc, Boulder, CO) and PEA (Olink Proteomics, Uppsala,
Sweden) are emerging technologies, capable of simultaneously measuring
thousands of plasma proteins. While SomaScan uses fully synthetic, singlestranded DNA-based molecular recognition elements to bind to proteins within a
sample,[96] PEA employs oligonucleotide-labeled antibody probe pairs that bind
to their respective proteins. Both are semi-targeted, high throughput analytical
platforms with increased usage in recent biomarker research.[97-100] Their use
requires less infrastructure, lesser number of steps in sample preparation and
much less expertise when compared to MS.[101] Because they are semitargeted, their use challenges the fundamental principle of unbiased proteomic
profiling for the purposes of biomarker discovery and hypothesis generation.
This, however, may be less of a concern given that newer version of SomaScan
can identify 7000 different proteins from only 55µL of sample.
(https://somalogic.com/panels/, last accessed 05/29/2022).

Nonetheless, MS remains the gold standard platform, although data from the
different platforms may be complimentary.[101] Because SomaScan and PEA
require less sample preparatory steps, the analytical challenges with the human
plasma proteome, outlined earlier in this chapter, may only apply to biomarker
workflows that employ MS. The extent to which additional steps such as sample
fractionation and immunodepletion,
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Figure 1. 4 Mass spectrometry analysis of a plasma sample
Tryptic peptides from a plasma sample spiked in with exogenous CDS1 protein
was analyzed on the Orbitrap Fusion Lumos MS. Peptides were fragmented by
electron transfer dissociation (ETD) and the resulting MS/MS spectra were
search against the human proteome database using COMET. A: Base peak of
the total ion chromatogram based on the peptide separation by liquid
chromatography. B: MS1 spectra acquired at 22.9 mins retention time (red
arrows). Image source: MASSIEVE, an in-house computational platform
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or the lack thereof, affects data acquired by SomaScan or PEA remains to be
determined.

Overcoming the validation bottleneck
Although biomarker researchers agree that discovery, verification and validation
are the major steps in the workflow (Figure 1.3), two major approaches to this
workflow also exist. The first and more traditional approach, also called the
triangular strategy, is based on discovery using MS, followed by verification and
validation with immunoassays (Figure 1.5). Quite recently, Geyer, Holdt [30]
proposed the rectangular strategy, which involves the discovery, verification and
validation of candidate biomarkers all on the same MS platform. As outlined
earlier regarding challenges with immunoassay-based validation schemes, the
rectangular strategy seeks to eliminate this bottleneck in the biomarker workflow.

Initial steps in MS-based validation involve the development of a targeted method
for the list of precursor ions discovered a priori. In targeted proteomics, the term
“transition” refers to the pair of precursor ion – product ions following
fragmentation. Broadly, selected reaction monitoring (SRM) and parallel reaction
monitoring (PRM) are the available targeted proteomic methods, the choice of
which is dictated by the available MS instrument and the nature of the
experiment or type of information required. While SRM, primarily performed on
20

triple quadrupole (QqQ) MS, requires the selection of a limited number of
transitions for a given peptide, PRM monitors all potential product ions of a
peptide.[102] The method development is achievable directly via the MS
instrument software (e.g., XCalibur) or with the assistance of specialized
software (e.g. Skyline).[103] Specifically for PRM, the method file typically
contains an identifier for the precursor ion, the m/z, the charge state of the
precursor ion, and the corresponding retention time window, all of which can be
obtained from the discovery experiments. SRM requires the additional step of
specifying which transitions will be monitored at MS2.

Following data acquisition by targeted proteomics, Skyline can also facilitate
additional downstream analyses, although vendor software such as QualBrowser
or manually extracting the data in a programming environment are possible
options. Because retention time windows are specified for any given precursor
ion, particular attention on RT is required as minor changes in chromatographic
conditions occurring during MS can cause significant RT shifts. Figure 1.6 shows
the RT shifts observed during an in-house PRM method development on a 1hour gradient. We observed that for each subsequent MS run, there was a RT
shift of about 30 seconds.

21
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Figure 1. 5 Different approaches to the discovery pipeline
Consistent in both approaches is the unbiased profiling of biospecimen in the
discovery phase, and an orthogonal biomarker measurement and use of
independent set of samples in the subsequent phases. A: triangular strategy
typically begins with a smaller set of samples, yielding 1000s of candidate
biomarkers and ends with larger cohort of patients to validate a smaller panel of
biomarkers; B: in the rectangular approach, both discovery and validation occur
on the same MS platform without a need for affinity-based validation. Emphasis
here is on orthogonality of the MS measurement techniques across the different
phases of the pipeline. Qualification, verification and validation are illustrated in a
continuum to demonstrate how MS eliminates bottlenecks and simplifies the
biomarker pipeline
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Although this problem is not well known in published literature, Heil, Remes [104]
made a similar observation direct import of acquired raw data after each run in
order that RTs can be adjusted for subsequent runs. Nonetheless, the advantage
of MS-based validation over traditional affinity-based methods is clear, with the
theoretical possibility of shortening the bench-to-bedside time gap in biomarker
discovery.

Post-operative delirium
We apply the biomarker pipeline to the context of post-operative delirium. This is
a debilitating clinical condition with acute onset and a fluctuating course in the
immediate post-operative period. It is characterized by changes in cognition,
deficits in attention, fluctuating levels of consciousness and/or disorganized
thinking.[105]

It is the most common acute neuropsychiatric disorder[106, 107] and complicates
post-surgical care of the elderly with worse hospital outcomes, longer hospital
stays, higher risk of post-surgical strokes, increased readmission rates and
higher overall mortality[108, 109]. Post-operative delirium increases
hospitalization cost substantially and remains a significant healthcare burden,
most especially in the geriatric population. Although incidence varies widely
depending on the type of surgery,[110] the post-cardiotomy population has one
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Figure 1. 6 Retention time shifts
Even when a wider RT window is specified for a given precursor, RT shifts
across MS runs can be significant enough such that precursor ions may be
missed. Target proteomic analyses involving many samples or runs require
particular attention to this shift in RTs
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of the highest incidence, documented to be over 50% in some studies.[108, 111,
112]

Complications of post-operative delirium goes farther than the immediate postsurgical period. In the balanced trial, Evered, Chan [113] observed that patients
diagnosed with delirium in the immediate post-operative period experienced
significant neurocognitive deficits in the one year following the surgical insult.
Significant functional decline, which necessitates placement in nursing homes,
has also been reported at three month following surgery.[114, 115] Although
delirium is generally considered a transient condition, some patients continue to
meet the criteria of diagnosis one year after discharge.[116, 117] This
phenomena, conveniently termed persistent delirium, is associated with overall
higher risk of mortality and delayed functional recovery.[118] Furthermore,
delirium may accelerate long-term cognitive disorders such as Alzheimer’s
disease, although this observation has been inconsistent across studies.[119121]

At present, no definitive treatments exist for delirium. Because patient
management is largely symptomatic, there is high demand for preventative
strategies. Prevention, however, requires finding subjects who are most at risk of
delirium, or at least, accurately identifying patients before overt clinical
manifestation. Unfortunately, the existing diagnostics tools require that patients
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are already exhibiting signs of delirium. The confusion assessment method
(CAM), the Intensive Care Delirium Screening Checklist (ICDSC) and the 4A’s
test (4AT) are common delirium screening tools. Of these, the CAM and its
accompanying variants (CAM-S, CAM-ICU, 3D-CAM, etc.) are the most widely
used[122] with four main components based on the 1987 DSM III-revised
criteria.[123] Despite a reasonably good diagnostic accuracy of the CAM (>94%
sensitivity and 90-95% specificity), there is significant diagnostic uncertainty.
Assessing for confusion and disorganized thinking introduces subjectivity and
arbitrariness. Even for trained users of the tool, there is poor inter-rater
agreement, reported to be about 92%.[124] Furthermore, delirium remains one of
the most missed- or under-diagnosed conditions in current practice. Between 32
– 72% of cases have been reported as missed diagnosis, misattribution or late
diagnosis.[125-127] Additionally, the hypoactive subtype of delirium often
presents with features that are not always associated with phenotypic
delirium.[128, 129]

Due to aforementioned problems, the current assessment tools may not be very
helpful for a condition that has no definitive treatments, and for which early case
identification and prevention is desired. We therefore assert that reliable
diagnostic biomarkers of delirium are urgently needed.
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Research Objectives
In this doctoral research, I hypothesize that biomarkers of delirium, discovered by
comprehensively profiling the plasma samples of delirium cases and non-delirium
controls, may provide an objective approach to diagnosis and offer insights into
possible neuronal pathomechanisms. Comprehensively profiling of patient
samples requires that the initial stages of the biomarker discovery workflow is
unbiased, to allow for the detection of all possibly identifiable proteomic
signatures between cases and non-cases.

To achieve this overarching research objective, Chapter Two[130] is a systematic
review that summarizes the major proteomic studies over the last six years that
sought to discover biomarkers of delirium using unbiased, systems-biology
approaches. This study provides a birds-eye view of the attempts and
approaches by various scientists towards the clinical need of discovering
biomarkers of delirium. Further, the review provides a thorough assessment of
experimental approaches that optimize the chances of a successful discovery
endeavor, lessons from previous attempts and avenues for improvement in the
quest for diagnostic biomarkers of delirium.

Consistently emphasized in this doctoral thesis is the knowledge that discovery
experiments be conducted in an unbiased manner, most especially for a
condition such as delirium for which much less is known about the underpinning
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pathomechanisms. This approach to biomarker discovery, appropriately termed
as untargeted experiments, requires that selection of candidate biomarkers be
guided by the data acquired. Quite surprisingly, most studies on delirium
biomarkers use a targeted approach, where a list of proteins are selected for
measurement in cases and controls. The use of targeted approaches, while
powerful, is unavoidably biased by the a priori knowledge of those biomarkers. In
Chapter Three[131] of this document, I describe a targeted study of plasma
samples in our cohort based on select panel of four proteins. I demonstrated that
use of targeted strategies for the purposes of discovery defies the fundamental
logic of biomarker discovery and may potentially lead to misleading conclusions
and incorrect study outcomes.

Lastly, I applied the biomarker discovery pipeline to plasma samples from subject
in our study cohort. Chapter Four[132] outlines the discovery steps, the
application of advanced computational tools to handle low-abundance proteins
and validation strategies that ensured the accurate quantification of discovered
biomarkers in an independent set of samples. It is my hope that this series of
works contributes to the growing body of knowledge on clinical proteomics,
biomarker discovery and the search of objective diagnostic biomarkers of postoperative delirium.
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Chapter Two: Review of Proteomic Contributions to
Delirium Biomarker Research
Wiredu, K., et al., Proteomics for the discovery of clinical delirium biomarkers: A
systematic review of Major Studies. medRxiv, 2022[133]
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Abstract
Delirium represents a significant healthcare burden, diagnosed in over two million
elderly Americans each year. In the surgical population, delirium remains the
most common complication among elderly patients and is associated with with
longer hospital stays, higher costs of care, increased mortality and functional
impairment. The pathomechanism of disease is poorly understood, with current
diagnostic approaches somewhat subjective and arbitrary, and definitive
diagnostic biomarkers are currently lacking. Despite the recent interest in
delirium research, biomarker discovery for it remains new. Most attempts to
discover biomarkers are targeted studies that seek to assess the involvement of
one or more members of a focused panel of candidates in delirium. For a more
unbiased, systems-biology view, we searched literature from MEDLINE,
Cochrane Central, Web of Science, SCOPUS, and Dimensions between 2016
and 2021 for untargeted proteomic discovery studies for biomarkers of delirium
conducted on human geriatric subjects. From an overall search of 1172
publications, eight peer-reviewed studies met our defined inclusion criteria. The
370 unique peri-operative biomarkers identified in these reports are enriched in
pathways involving the activation of the immune system, inflammatory response,
and the coagulation cascade. IL-6 was the most commonly identified biomarker.
By reviewing the distribution of protein biomarker candidates from these studies,
we conclude that a panel of proteins, rather than a single biomarker, would allow
for discriminating delirium cases from non-cases. The paucity of hypothesis-
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generating studies in the peer-reviewed literature also suggests that a systemsbiology view of delirium pathomechanisms has yet to fully emerge.

Introduction
Diagnosed in over 2 million older adults each year, delirium presents a significant
healthcare burden in the United States.[134, 135] Delirium is etiologically
heterogenous, with many precipitating and predisposing factors.[136-138]
Following surgery, it complicates geriatric hospitalizations with significant
functional impairments, longer hospital stays, higher cost of care and increased
overall mortality risk.[109, 139, 140] Despite the substantial impact on the quality
of life in this demographic, delirium is diagnosed through subjective assessment
of a constellation of signs and symptoms within the clinical history, behavioral
observation and cognitive assessments.[141] As a results, commonly used tools
such as the confusion assessment method (CAM) often exhibit inter-rater
variability.[142, 143]

In addition, there is considerable lack of clarity regarding the pathophysiology of
the condition. Given this, it is surprising to note the majority of delirium biomarker
research use targeted experiments, where authors study a selected list of
biomarkers. The use of targeted strategies for the purposes of discovery, while
powerful, is unavoidably biased by the a priori knowledge of those biomarkers
and the specific focus of the hypothesis under evaluation. Targeted studies may
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miss as-of-yet unappreciated functional players in a condition as complex as
delirium. Furthermore, the biological complexity of commonly used biofluids
(such as blood and cerebrospinal fluid) necessitate the use of a measurement
platform that is precise and sensitive even for biomarkers of low abundance.
Mass spectrometry (MS) remains the gold standard protein discovery platform,
although high-throughput platforms such as SomaScan and proximity extension
assays (PEA) have recently been used.[101, 144, 145] Unlike MS, these
platforms are semi-targeted and limited in the number of proteins assayable.

The inception of the Network of Investigation of Delirium: Unifying Scientists
(NIDUS)[146] in 2016 to corroborate scientific evidence on delirium has
encouraged a more unified nomenclature[147] and consistency in case
identification for the purposes of research. However, only a small proportion of
published literature since 2016 has focused on biomarker identification (figure
2.1).

The identification of definitive biomarkers of delirium is likely to contribute
significantly to our understanding of delirium pathophysiology and to accurately
identify cases of this acute and debilitating condition.[148] Here, we have
summarized proteomic contributions in delirium biomarker research in the last six
years (2016 – 2021), focusing on untargeted experiments that offer a systemsbiology view of the condition. We examine the merits of the different
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Figure 2. 1 Counts of all published documents on delirium between 2016 and
2021
Figure highlights documents involved with delirium biomarkers only, or delirium
treatment and prevention. Documents described as articles include peerreviewed original research, study protocols, preprints, poster abstracts,
monographs, conference proceedings and editorials and opinions. Administrative
documents include grants, patents, clinical trials and policy documents. (Source
of data: Dimensions.ai[149], downloaded on 03/25/2022)
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measurement platforms and experimental approaches and have offered
perspectives on optimizing sample preparation for the detection of low
abundance biomarkers. Lastly, we analyzed the biomarker pool from the
published studies for understanding of functional themes that may be at play in
the occurrence of delirium.

Methods
Following the PRISM guidelines,[150] we searched five databases (MEDLINE,
SCOPUS, Central, Web of Science and Dimensions) using the key terms
[delirium, acute confusion, acute brain failure] AND [biomarker, biological marker]
AND [proteins, proteomics] (Supplemental Table 1). Search results were limited
to publications written in English and published from 2016 – 2021. EndNote
bibliography software version X9.3.3[151] was used for duplicate removal. All
remaining publications were independently reviewed by KW and EAP in a twostage process. Rayyan freeware, a free web-tool for systematic reviews,[152]
was used to expedite the initial (title and abstract) screening. Secondary
screening of remaining publications involved full text review for publications that
met the inclusion criteria of (1) untargeted proteomic profiling, (2) for biomarkers
of delirium, (3) conducted on human geriatric subjects. Discordance was
resolved by both KW and EAP through consensus.

35

Results
We identified a total of 1,172 publications from 5 database searches (MEDLINE,
SCOPUS, Central, Web of Science and Dimensions). The majority of articles
excluded during initial screening were review articles, non-biomarker articles,
poster abstracts, meeting proceedings, editorial and comments. Full text review
was performed on 280 articles, many of which were either targeted biomarker
studies on delirium, animal studies or involved non-protein delirium biomarkers
such as brain imaging. Unique in these exclusions was one study on delirium in
children. Figure 2.2 is a flowchart of the screening steps and exclusion criteria,
leading to the final eight peer-reviewed original studies summarized in Table 1.
Of the eight studies, five were conducted in North America [1, 2, 5, 7, 8] and one
each in Asia [3], Europe [6] and Sweden [4].

Study Design, Patient Selection and Choice of Controls
All but two studies had a nested, case-control design.[4, 6] Overall, the age of
delirium cases averaged 73.3 years (Table 1). Samples from a total number of
484 subjects (cases and controls) were used for biomarker discovery alone,
although there is likely an overlap in subjects selected from the same parent
study (i.e., the SAGES study or the MINDDS trial). Except for one study which
profiled biofluids from non-surgical patients[6], eligible subjects were all surgical
patients, who underwent either cardiac[5, 8] or non-cardiac procedures.[1-4, 7]
Patients’ comorbidity score, either with the Charlson index or PROMIS, was
established in all but for two studies[4, 6], although van Ton, Verbeek [6]
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Figure 2. 2 Literature search and screening
PRISMA flow chart highlights the step-by-step process involved in the selection
of the final 8 studies summarized in this review.
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indicated that hypertension, diabetes, immunosuppression and cerebrovascular
disorders were common in the selected cohort.

Delirium cases were identified with either the Confusion Assessment Method
(CAM), the Chart-based Delirium Identification Instrument (CHART-DEL) or the
Diagnostic and Statistical Manual of Mental Disorders (DSM-V) (Table 1).
Subjects from the MINDDS trial [5, 8] received twice daily post-operative
assessments for delirium occurrence, compared with once daily assessments for
the SAGES cohort [1, 2, 7].

Baseline neurocognition of study participants was established in seven studies
(Table 1). Neither the case identification method nor baseline neurocognition
approach was specified by Lindblom, Shen [4]. All eight studies used nondelirium controls to establish a statistical baseline, with some variations in the
choice of controls. Controls were age- and sex-matched in five studies [1, 2, 5, 7,
8], although the SAGES cohort included baseline cognitive performance as an
additional matching parameter. Han, Chen [3] selected controls that matched to
cases by age and by mini-mental state examination (MMSE). In the study by van
Ton, Verbeek [6], two groups of controls to the post-infectious delirium cases
were selected: healthy controls and controls with neurocognitive impairments
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other than delirium. Similarly, Lindblom, Shen [4] selected surgical patients who
suffered other neurological injuries but without the diagnosis of delirium.

Sample Preparation and Proteomic Techniques
The source of proteins for biomarker discovery included peripheral blood (five
studies), cerebrospinal fluid (CSF; two studies) and both blood and CSF (one
study) (Table 1). When CSF was used, lumbar puncture samples were collected
only once. This contrasts with the serial collection of samples for the blood-based
studies. Three of the six blood-based studies used plasma and the remaining
three used serum. Of note, only the plasma-based studies [1, 2, 7] documented
sample immunodepletion, specifically by using affinity-based depletion columns
to remove the 14 most abundant proteins in an effort to detect proteins of lower
abundance. Three studies used mass spectrometry (MS) as the analytical
approach, three studies used proximity extension assays (PEA), and the
remaining two used SomaScan technology. Two studies attempted sample
multiplexing with isobaric labelling [1, 2]. There was, however, no mention of preanalytical sample fractionation to further reduce sample complexity in any of the
studies.
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Table 2. 1 Summary of included studies
*: mean age of delirium cases and non-delirium controls (in years)
: number of cases and controls in the discovery phases of experiment

^

: authors reported a combined mean age of all subjects

†

§

: total number of proteins identified (not necessarily what was used for

downstream analysis)
¶, ∂

: subjects were likely selected from the same parent study, SAGES and

MINDDS, respectively

Abbreviations:
AD: Alzheimer’s disease; AZGP1: zinc-alpha-2-glycoprotein; CAM: confusion
assessment method; CHART-DEL: Chart-based Delirium Identification
Instrument; CPB: cardiopulmonary bypass; CRP: c-reactive protein; CSF:
cerebrospinal fluid; DSM-V: Diagnostic and Statistical Manual of Mental
Disorders (5th edition); ELISA: enzyme-linked immunosorbent assay; EZH2:
histone-lysine N-methyltransferase; FGF: fibroblast growth factor; GCP: general
cognitive performance; IL-2 / IL-6: interleukin 2 / interleukin 6; iTRAQ: isobaric
tags for relative and absolute quantification; KLF6: krueppel-like factor 6; LCMS/MS: liquid chromatography – tandem mass spectrometry; MCP-3: monocyte
chemotactic protein-3; NCog: baseline neurocognition; PDE3A: cGMP-inhibited
3',5'-cyclic phosphodiesterase A; PEA: proximity extension assay; POD: postoperative delirium; PRM-MS: parallel reaction monitoring – mass spectrometry;
tMOCA: telephone-based Montreal cognitive assessment; TR4: nuclear receptor
subfamily 2 group C member 2
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Proteomic Biomarkers
In the union of all eight studies, 446 unique proteins were identified as candidate
biomarkers for delirium. Of these biomarkers, 370 were identified perioperatively. Figures 2.3 and Figures 2.4 illustrate the contribution of each study
to the total pool of candidate biomarkers, and where biomarkers overlap between
studies. Overall, Vasunilashorn, Dillon [7] reported the largest number of
differentially abundant proteins (n = 128) between cases and controls.
Interleukin-6 (IL-6) was the most commonly identified, differentially abundant
protein among the studies [4-8]. Complement component C9, antithrombin-III
(SERPINC1), the cytokine fractalkine (CX3CL1) and chitinase-3-like protein 1
(CHI3L1) are notable biomarkers that were found in three or more studies.
Except for the studies done in the SAGES cohort [1, 2, 7], very few of the
remaining proteins overlap between studies.

Functional analysis on the biomarker pool of 370 proteins for enriched biological
processes suggests a systemic response of widespread activation and
dysregulation of proteins involved in immunological reactions, inflammatory
responses, and the coagulation cascade (Figures 3A, 3D). Furthermore,
subcellular ontology annotation reveals the extracellular region as the
predominant native location of these dysregulated proteins, enriched in signaling
and cytokine activity (Figures 3C, 3D).
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Figure 2. 3 Modified Venn (Euler) diagram
Modified Venn (Euler) diagram showing the intersecting biomarkers
between the 8 studies. Size of circle is proportional to number of biomarkers.
Colors represent studies from the same cohort, with likely overlap in the subjects
selected for proteomic profiling. Thickness of circle outline indicates the type of
biofluid used. NB: Intersections between 4 or more studies are not visualized
here.

48

Figure 2. 4 UpSet chart
Figure shows the contributions of each study to the total pool of 446 unique
biomarkers, and all the intersecting sets of proteins that could not be illustrated in
figure 2 (main). Same colors represent studies from the same cohort, with likely
overlap in the subjects selected for proteomic profiling. Thickness of rectangle
outline indicates the type of biofluid used.
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Validation Approaches
All three mass spectrometry-based studies and one SomaScan-based study
performed protein verification and validation on candidate biomarkers identified
by high throughput methods (Table 1). Of these studies, three used ELISA, an
affinity-based approach[1, 2, 7] and the remaining study used a MS-based
approach, specifically parallel reaction monitoring (PRM).[3] The choice of
biomarkers that were validated is however varied. Of the 63 differentially
abundant proteins in the study by Han, Chen [3], 20 were selected for validation
by PRM based on a minimum number of peptides and transitions set by the
authors. Of the remaining studies, the choice to validate CRP, SERPINA3,
AZGP1 and CHI3L1 was based, partly, on the consistency of their identification
in various samples, the availability of a commercial antibody and a series of
binomial, signed rank and Student t-tests.

Discussion
We have presented an in-depth review of clinical proteomic contributions over
the preceding six complete years that offered an unbiased systems-biology view
of delirium. As consistency in case identification and unified nomenclature is
necessary to make comparisons between studies, we began our literature search
from 2016. We observed that this is also the year NIDUS was established,[146]

50

Figure 2. 5 Functional analysis of the biomarker pool
Functional analysis of the biomarker pool showing the top 10 GO terms with
regards to (A) biological processes, (B) cellular component, and (C) molecular
functions. The number of proteins involved in each of the major functional
classes in the biomarker pool are shown in (D).
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and interest in delirium research has seen a steady increase since that point. We
focused on studies that measured delirium biomarkers using a discovery-based
approach in the human geriatric population. The total of eight studies that met
our criteria signify the paucity of literature that offers a systems-biology view of
delirium in this demographic. Nonetheless, the large proportion of search results
that were excluded as grants, conference abstracts, meeting proceedings, and
posters suggest a growing interest in research on delirium diagnostics.

We aggregated a total of 446 biomarkers that are differentially dysregulated in
human patients with delirium across eight studies. It is worth noting that subjects
in one study [6] developed delirium after an infectious process. Functional
analysis of the 370 peri-operative pool of biomarkers suggests a widespread
activation of immunological reactions, inflammatory responses, and the
coagulation cascade. We focused functional analyses only on biomarkers
discovered peri-operatively, given that infectious delirium may involve a different
pathophysiological process[6, 153-155], although analyses of all 446 biomarkers
did not reveal any functional differences. Given that IL-2, C-X-C motif chemokine
11 and C-C motif chemokine 13 [1, 5, 7], among others, were elevated
preoperatively, it is equally likely that a heightened pre-operative inflammatory
state increased the risk of delirium, although functional studies would be required
to rigorously test this hypothesis. This observation is consistent with prevailing
knowledge that phenotypic delirium is a culmination of multiple predisposing and
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precipitating factors [138, 156, 157], and predictive biomarkers may be more
beneficial in certain risk groups than others.

At the cellular level, the biomarker pool is enriched in signaling and cytokine
activity, predominantly in the extracellular domain. While there are many
extracellular domain-containing proteins that do not localize to synapses, this
observation may signify the possibility of altered synaptic functioning in the
context of delirium. Synaptic dysfunction is an early event in Alzheimer’s disease
[158], and many researchers have suggested similar findings as a common
pathophysiological starting point in the continuum of neurocognitive disorders, of
which delirium and AD are a part [159-161].

Interleukin-6 remains one of the most consistently identified proteins among
delirium patients. In well-functioning older patients, IL-6 is found to be
prospectively associated with cognitive decline [162-164]. IL-6 is part of the core
panel of frailty biomarkers [165], and has recently been suggested by GómezRubio, Trapero [166] as a useful biomarker for monitoring treatment in frail
individuals. The inflammatory role of IL-6 and its associations with
aforementioned predisposing triggers further emphasize the neuro-inflammatory
model of delirium.
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Notable in the 24 overlapping proteins between Dillon, Vasunilashorn [2] and
Vasunilashorn, Ngo [1] is CRP, an acute phase reactant and a non-specific
marker of inflammation, infection and tissue injury [167]. Many authors have
suggested elevated CRP levels to be associated with a higher risk of delirium
occurrence [168-173], and could likely be used to monitor the clinical course of
delirium [174]. In a recent meta-analysis of 54 observational studies, Liu, Yu
[175] hinted that CRP may be a more specific marker of post-operative delirium
(POD) than post-operative cognitive dysfunction (POCD). The clinical relevance
of this specificity remains unclear, given that a lower baseline cognitive reserve is
a precipitating factor for both POD and POCD [176].

It is well documented that elevated total cholesterol and LDL correspond to
increased neuritic plaque density in Alzheimer’s disease [177, 178]. One
overlapping protein, apolipoprotein A-IV (APOA4) is a component of
chylomicrons and HDL, synthesized mainly in the intestine and secreted into
plasma [179]. Although there is some tenuous evidence of an association with
cognitive impairment and Alzheimer’s disease [180, 181], data on APOA4 is
scarce and there has yet to be a formal interrogation of its association in delirium.
This holds true for many proteins in this union of 446 biomarkers.

Furthermore, it is also unclear how the modest degree of overlap in candidate
biomarkers between the eight studies reflect differences in the biofluids used or
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the analytical strategies used to identify the biomarkers. While MS relies on
peptide spectrum matches for protein identification, PEA (Olink Proteomics,
Uppsala, Sweden) is an oligonucleotide-based immunoassay that combines
quantitative real-time PCR with high-throughput quantification. SomaScan
(SomaLogic, Inc, Boulder, CO), on the other hand, uses aptamers to bind
specific molecular targets. These affinity technologies have recently gained
attention in plasma proteomics as they are cost-effective, require less expertise,
much smaller sample volumes and can quantify a little over 1000 human plasma
proteins. In fact, the number of recent original publications on plasma proteomics
that use PEA outnumber those that present MS-based approaches [101].
Despite reports of comparable reproducibility and complementarity of PEA and
SomaScan to MS, a recent study comparing PEA to MS-based protein profiling
revealed a similar modest degree of overlapping proteins as found in this review
[101]. Of the 14 available PEA panels, van Ton, Verbeek [6] and McKay, Rhee
[5] used the two that predominantly assay neural and inflammatory markers. It is
therefore not surprising that there are nine overlapping biomarkers between
these two studies. The SomaScan-based studies had only one biomarker in
common, namely IL-6. Given that these affinity-based platforms are semitargeted and predominantly assay the low abundance plasma proteome, it is our
thinking that the strengths of all three analytical techniques could be viewed as
complementary, offering a deeper view into the plasma proteome together than
each would separately.
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Three of the six blood-based studies used serum which is qualitatively and
quantitatively different from plasma. Removal of clotting factors (largely
fibrinogen) results in a 3 – 4% lower protein concentration in serum relative to
plasma [65, 66], and may also lead to removal of proteins with specific (or nonspecific) interactions with fibrin in a manner that is unpredictable. The Human
Proteome Organization (HUPO) therefore endorses the use of plasma, citing a
lower degree of ex vivo degradation and recommends that citrate or EDTA be
used for anticoagulation over heparin [67]. As the sample choice should be
tailored to the specific biomarker needs and the biomarker landscape of delirium
is still in its infancy stages, it would be preferable that the biofluid used, their
collection and sample preparation protocols permit the study of the entire plasma
proteome.

Serial collection of samples in the blood-based studies allowed for the
determination of temporal associations of proteomic changes with the occurrence
of delirium. In all but one of the blood-based studies [4], a minimum of two
samples were collected for each study participant: at baseline (pre-operative)
and on post-operative day one. This is in sharp contrast to the CSF-based
studies which were limited by the one-time sample collection by lumbar puncture.
CSF is the proximal biofluid of choice with a greater likelihood of reflecting the
immediate proteomic changes in the brain. Unfortunately, CSF access is
severely limited by the invasive nature of the sampling technique (lumbar
puncture). Furthermore, it is hypothesized that the relatively higher permeability
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of the blood brain barrier of the elderly brain makes it possible for proteomic
changes in CSF to be detected in plasma.

Immunodepletion is generally thought to be beneficial because of the wide
dynamic range (~1010) of protein abundances in plasma and CSF, dominated by
a handful of highly abundant proteins such as albumin and immunoglobulins.
This makes identifying and quantifying proteins of lower abundance otherwise
difficult. Three of the eight studies reported use of immunodepletion on the
samples prior to analysis. Given that PEA and SomaScan are semi-targeted, it is
unclear if immunodepletion is a necessary pre-analytical step. The extent to
which the use immunodepletion, or otherwise, affected the identification of
candidate delirium biomarkers is unclear. In addition, fractionation strategies
such as ion exchange chromatography significantly reduce sample complexity
and increase the depth of proteome coverage, especially when searching for low
abundance plasma proteins. With the collective results from all eight studies
indicating possible neuro-inflammatory process(es) to play a prominent role in
delirium pathogenesis, candidates-biomarkers of delirium are likely to be in the
low abundance proteome, which makes use of immunodepletion and sample
fractionation an important consideration in the experimental design. Clearly, the
relative advantages and disadvantages of each sample type and the approach to
sample preparation will continue to play a significant role in the design of future
studies to identify protein biomarkers in delirium and neurocognitive disorders at
large.
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Integrating results from eight different studies was not without challenges, one of
which was the use of different delirium diagnostic algorithms. Even within the
same study, Dillon, Vasunilashorn [2] employed both CAM and chart review for
delirium case identifications. Further, the inclusion of subsyndromal delirium
(SSD) cases together with delirium cases in the studies by Dillon, Vasunilashorn
[2], Vasunilashorn, Ngo [1] and Vasunilashorn, Dillon [7] may further complicate
data interpretation in the context of other studies. Additionally, none of the
studies formally screened for depression among the study subjects.

Lastly, nested case control is an adequate study design for biomarker studies. It
is however limited in precision, inferential conclusions and power due to sampling
of controls. Only associations, and not causal inferences, can be concluded from
nested designs, even after adjusting for most confounding variables [182, 183].
The choice of controls to establish a statistical baseline plays a significant role in
subsequent differential abundance analyses. In the study by van Ton, Verbeek
[6], controls were significantly younger than delirium cases (49.3 versus 64.2
years). Nonetheless, this is the only study in which authors excluded control
subjects with a known acute or chronic systemic inflammation.
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Conclusion
The urgent need for diagnostic and predictive biomarkers of delirium is important
not only to correctly identify cases, but also for pre-operative risk stratification
and for follow-up on possible long-term neurocognitive sequelae. Interest in
delirium research has seen a steady rise since the inception of NIDUS in 2016.
Nonetheless, delirium biomarker research appears to be just emerging. There
are only a handful of studies that offer a systems-biology view of delirium from
human patient samples. For diagnostic purposes, it appears likely that a panel of
biomarkers, rather than a single biomarker, has potential for discriminating
delirium cases from non-cases. Collectively, biomarkers from these studies
suggest an immunological and inflammatory response following surgical insult,
enriched in cytokine and signaling activity in the extracellular space. Further
studies are warranted to support this observation. With a greater focus on the
low-abundance plasma proteome, complementary use of MS and PEA may yield
a deeper plasma proteome profiling.
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Abstract
Background
60

Neurologic and neurobehavioural complications are common after cardiac
surgery with cardiopulmonary bypass (CPB). Exposure to the artificial bypass
surface, conversion to laminar flow and hypothermia likely contribute to systemic
inflammation observed after CPB. To ensure adequate systemic oxygenation, the
CPB patient is often exposed to supraphysiologic levels of oxygen. Relative to
normoxia, perioperative hyperoxia during CPB has not been shown to impact
neurocognition in the long-term. Whether this holds true for the immediate postoperative neurocognitive function is the question of this nested case-control
study.
Methods
46 age- and sex-matched subjects, aged ≥ 65 years, selected for this study were
randomized to receive normoxia or hyperoxia during CABG with CPB in the
parent trial. Levels of four neuroinflammatory biomarkers (S100B, ENO2,
CHI3L1, UCHL1) were measured at baseline and at post-bypass. Baseline
neurocognition was established with the Montreal Cognitive Assessment tool and
patients were assessed on each post-operative day for delirium using the
confusion assessment method. Mediation analyses was conducted for the
conditional effect of perioperative oxygen treatment on the occurrence of
delirium, assuming mediation effect from change in biomarker levels.
Results
26 subjects (n = 12) demonstrated delirium. Of the four biomarkers, only S100B
levels were differentially abundant post-bypass regardless of treatment (8.18
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versus 10.15pg/mL, p value < 0.001). We found significant direct effects of
treatment and the interaction of treatment and baseline neurocognition in the
occurrence of delirium (effect = 0.08, p = 0.013). There was no significant
mediating effect of S100B levels.
Conclusion
While perioperative hyperoxia may not be associated with neurocognitive
dysfunction in the long-term, its immediate effects may contribute significantly to
the occurrence of post-operative delirium. Taken together, our findings suggest a
dose-response-time relationship between hyperoxia and neurocognitive function.
Introduction
The effects of perioperative hyperoxia on myocardial damage, acute kidney injury
and long-term neurocognitive dysfunction are well documented [184-189], but the
impact on the immediate post-operative neurocognitive function is less wellcharacterized [190]. Globally, over 1.25 million patients undergo cardiac surgery
on cardiopulmonary bypass (CPB) each year [191]. Perioperatively, the CPB
population are often exposed to supraphysiologic concentrations of oxygen [192].
This practice is premised on the primary goal of maintaining end-organ perfusion
as hypothermia, microcirculatory heterogeneity and interstitial fluid shifts during
CPB all contribute to poor tissue oxygenation [193].

At the tissue level, hyperoxia is beneficial in the ischemic preconditioning of the
myocardium, reduces overall gas microemboli and provides significant oxygen
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reserves in the event of interrupted ventilation [194-196]. In fact, the ability to
monitor regional cerebral oxygenation in real-time has provided unequivocal
evidence linking cerebral desaturation during CPB to worse clinical outcomes
[197-200], further emphasizing the need for higher oxygen concentrations. On
the other hand, hyperoxia may also trigger vasoconstriction that further
compromises perfusion, may instigate inflammation and worsen ischemiareperfusion injury through increased oxidative stress [201-204]. Notwithstanding
these, the prevailing observation is that hyperoxia during CPB is not associated
with poor long-term neurocognitive outcomes [185, 188, 205].

Delirium is etiologically heterogeneous and lower pre-surgical cognitive function
is a recognized risk factor [206-208]. The extent to which perioperative oxygen
treatment modifies the occurrence of delirium in a typical CPB demographic with
suboptimal baseline neurocognition, however, remains largely unknown. In this
nested case-control study, we examined the conditional effect of perioperative
hyperoxia on the occurrence of post-operative delirium in an elderly cohort who
underwent cardiac surgery on CPB. Further, we measured a panel of
neuroinflammatory markers and ascertained their possible role in mediating the
hyperoxia-delirium relationship. Finally, we proposed a conceptual model
regarding the interaction between baseline neurocognition and perioperative
hyperoxia as they relate to post-operative delirium.
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Methods
Study design and Ethics approval
Subjects in this nested case-control study were selected from the parent clinical
trial [188, 209] that examined the effects of intra-operative oxygen therapy on
neurocognitive outcomes among cardiac surgical patients at the Beth Israel
Deaconess Medical Center, Boston MA (Trial registration number NCT02591589,
principal investigator: Shahzad Shaefi, registration date: October 29, 2015).
Subjects were enrolled between July 2015 and July 2017, and all patients
provided informed consent. Institutional review board (IRB) approval
2014P000398/33 was amended for the purposes of this current study on
09/17/2021 by the Committee on Clinical Investigations (CCI) at the BIDMC.
Figure 3.1 summarizes the design of the current study.

Patient population, Exclusion and Inclusion Criteria
Details of enrollment, exclusion criteria and treatment allocation are published
elsewhere [188, 209]. Briefly, eligible participants included patients 65 years or
older who were booked for elective CABG requiring CPB. Neurocognitive
assessment was achieved using the telephonic Montreal Cognitive Assessment
(tMoCA) as the primary endpoint. Post-operatively, subjects were assessed daily
for delirium as a secondary endpoint using the confusion assessment method
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Figure 3. 1 Experimental design
Schematic illustration of the nested case-control study, plasma sampling times
and biomarker measurements by bead-based multiplex assay. CAM: confusion
assessment method; CPB: cardiopulmonary bypass
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(CAM). Patients were excluded if they were undergoing emergent CABG, if they
required single-lung ventilation, CABG without CPB, intraoperative balloon
counter-pulsation or mechanical circulatory support. Subjects with MoCA scores
below 10 were also excluded.

Sample size calculation
Because quantitative studies on the selected biomarkers in the context of
delirium are largely unexplored, Cohen’s estimation of effect size [210] was used
to determine the optimal sample size at a significance level of 0.05 and a
statistical power of 80%. Further, delirium cases were matched to non-delirium
controls at approximately 1:3 ratio, to a total of 46 subjects in the current study.

Conduct of Study and Biomarker Measurements
Whole blood samples at baseline and post-bypass (P-BP) were collected into
4mL EDTA-treated tubes (BD Diagnostics) and centrifuged immediately.
Resulting plasma was stored at -80ºC until analyses. Limits of detection, limits of
quantification and linearity of biomarker signal were established using serial
dilutions of patient samples and laboratory standards. Biomarker measurements
were made using a custom R&D Human Premixed Multi-Analyte Panel, a
magnetic bead-based multiplex assay (Catalog Number: LXSAHM-04, Lot
Number: L140030). Analyte concentrations were determined by a 5-parameter
logistic (PL) regression computed from the standard curves. All biomarkers were
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measured in duplicates. For quality control, intra-assay variability was assessed
at a cut-off of 20%.

Statistical analyses
Descriptive statistics are presented as mean (standard deviations) or count
(proportion) for continuous and categorical variables, respectively. Duplicates
recordings of biomarkers were averaged and compared between groups using
Student’s t-test (paired, unequal variance). Stepwise regression was used to
identify clinical variables with the most predictive association to the outcome
variable (delirium). Structural equation modeling (SEM) was used to construct the
conceptual and statistical mediation models based on this subset of variables
(Figure 3.2). Assuming all effects to be linear, mediation analysis was then
performed to ascertain the total, indirect and direct effects of intraoperative
oxygen treatment on the occurrence of delirium, with post-bypass change in
biomarker levels as the assumed mediating factor. Here, the direct effect of
perioperative oxygen treatment was computed as the change in the odds of
developing delirium in patients receiving hyperoxia versus the odds of developing
delirium in patients receiving normoxia, when baseline neurocognition is fixed
(i.e., holding tMoCA score constant). Average tMoCA score was also defined as
the arithmetic mean of tMoCA scores for subjects in this nested cohort.
Significance of the mediation effects were computed by bootstrapping [211]. All
analyses were performed in R environment for statistical computing, v4.1.1 [212]
at a significance level ⍺ = 0.05.
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Figure 3. 2 Modelling for mediation analyses
A: Conceptual and B: Statistical models used in the mediation model to assess
the conditional effects of baseline neurocognition and intra-operative oxygen
treatment on delirium occurrence, and their indirect effect through change in
biomarker levels.
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Results
26% of subjects (n = 12) in the nested cohort demonstrated delirium
postoperatively. At baseline, delirium cases and non-delirium controls were
matched by age, sex and race (Table 3.1). Details of subjects’ comorbidities and
preoperative medications are reported elsewhere [188]. Intraoperatively, there
was no statistically significant differences in aortic cross-clamp or
cardiopulmonary bypass times between cases and non-cases. Baseline
neurocognition, as measured by the Montreal Cognitive Assessment (MoCA)
tool, was generally low in this cohort, and significantly lower among cases
relative to controls (p = 0.02). Of the non-delirium controls, 21% (n = 7) met the
criteria for subsyndromal delirium.

We measured four biomarkers well-documented to be markers of neuroinflammation. For quality control, we set an intra-assay variability cut-off of 20%.
Biomarker measurements with 20% coefficient of variation (%CV) or higher
between duplicate runs were removed from all downstream analyses, although
including them did not change results of our analyses. Levels of ubiquitin
carboxyl-terminal hydrolase isozyme L1 (UCHL1) in all samples were below the
limits of quantification (Table 3.1 supplementary information).
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Table 3. 1 Baseline characteristics of study participants
Case
(N = 12)

Non-case
(N = 34)

p-value

Demographics
Age (years) 74 (±6.4)
70 (±4.3)
0.07
mean (SD)
Male sex
9 (75%)
27 (79%)
1
count (%)
BMI (count (%)
Underweight
1 (8%)
1 (3%)
0.12
Normal
2 (17%)
7 (21%)
Overweight
1 (8%)
13 (38%)
Obese
8 (67%)
13 (38%)
White race 10 (83%) 34 (100%)
0.11
count (%)
Baseline neurocognitive assessment
Pre-operative MOCA 15 (±2.7) 17 (±2.1)
0.02
mean (SD)
Intraoperative
Hyperoxia
4 (33%)
19 (56%)
0.31
count (%)
Cardiopulmonary bypass time (mins)
79 (±17)
81 (±24)
0.83
mean (SD)
Aortic Cross-clamp time (mins)
66 (±14)
67 (±21)
0.85
mean (SD)
Postoperative
Delirium severity score 8.9 (±3.1)
3.8 (±2.0)
< 0.01
mean (SD)
Sub-syndromal delirium
0 (0%)
7 (21%)
0.22
count (%)
┼4 subjects have missing data on CPBT and XCT, and 1 subject missing data on
delirium severity
Table 3. 2 Measured Biomarkers and their Dynamic Range
Analyte
Chitinase 3 -like 1
S100B
Enolase 2
UCH-L1

Dynamic Range (pg/mL)
438.44 – 106,540
40.41 – 9,820
374.44 – 90,990
925.10 – 224,800
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Of the remaining biomarkers, only S100B levels were significantly higher at postbypass relative to baseline levels (p value < 0.001, Figure 3.3). We found no
significant differences in S100B levels by sex or body mass index (BMI) at
baseline or post-bypass (Figures 3.4A, B, D, E). Stratified analyses also showed
that the absolute increase in S100B levels is not confounded by sex, BMI, patient
outcomes or intra-operative oxygen treatment (Figure 3.4C, 3F, Table 3.2). We,
however, observe that for patients with the longest CPB times (> 141 mins), the
absolute change in S100B levels was not significant (p = 0.076, Table 3.2).

Stepwise regression analyses revealed that baseline neurocognition and
hyperoxia were the most important predictors of the delirium. In our cohort, the
direct effect of baseline neurocognition on the occurrence of delirium is
modulated by perioperative oxygen treatment (direct effect = 0.078, p = 0.013)
(Table 3.3). Figure 3.5 illustrates the statistical mediation model and shows the
conditional effects of perioperative oxygen treatment when holding baseline
neurocognition constant. We also observe that this relationship is not mediated
by the post-bypass change in S100B levels (indirect effect = 0.002, p = 0.584).
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Figure 3. 3 Comparison of neuro-inflammatory biomarker levels
Boxplots show the quantile distribution (median and inter-quantile ranges) of
each biomarker, and a comparison of biomarker levels at baseline and at postbypass. Statistical tool used is the Student's t-test. Asterisks (*) represent
statistically significant difference (i.e., p value < 0.05); ns: not significant; S100B:
protein S100-B; ENO2: gamma-enolase; CHI3L1: chitinase-3-like protein 1.
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Table 3. 3 Stratified analysis of baseline to post-operative change in S100B
levels
Baseline
S100B
(pg/mL)

Postop
tS100B statistic
(pg/mL)

p-value

Overall
Stratified by outcome
Case
Non-case
Stratified by treatment
Hyperoxia
Normoxia
§
Stratified by BMI
Normal
Overweight
Obese
Stratified by Sex
Female
Male
Stratified by CPB Time
< 52 mins
52 – 112 mins
112 – 141 mins
> 141 mins

8.18

10.15

7.68

<0.001*

8.66
8.05

10.70
9.99

4.291
6.397

0.004*
<0.001*

8.08
8.30

10.10
10.21

5.015
6.057

<0.001*
<0.001*

8.17
7.81
8.47

10.61
10.03
10.01

4.125
5.907
3.824

0.004*
<0.001*
0.002*

9.09
7.96

10.65
10.03

3.372
6.922

0.015*
<0.001*

8.47
8.23
7.29
8.94

10.35
9.95
9.72
10.24

3.675
3.267
6.227
2.083

0.006*
0.014*
<0.001*
0.076

*: statistically significant difference at \alpha ≤ 0.05
§: Underweight category (n = 2) is underpowered for parametric testing
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Figure 3. 4 Stratified analysis of S100B levels
by: (A, B, C) sex and by (D, E, F) body mass index.
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Figure 3. 5 Mediation modeling and analyses
A. Statistical model of the relationship between delirium occurrence and the
interaction of baseline neurocognition and intra-operative oxygen treatment, with
an assumed mediation by post-bypass increase in S100B biomarker levels. B.
Conditional direct and indirect effect sizes quantified on the linear scale. Dashed
lines = non-significant relationship; MoCA: Montreal Cognitive Assessment tool
used to establish baseline neurocognition
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Table 3. 4 Conditional effects and regression coefficients of predictors in
mediation modeling
Variables
Δ(S100B)
Δ(S100B)
Δ(S100B)
Delirium
Delirium
Delirium
Delirium

Predictors
tMoCA
Treatment
tMoCA *
Treatment
tMoCA
Treatment
tMoCA *
Treatment
Δ(S100B)

Label
a1
a2
a3

β
-0.134
0.412
-0.364

CE
-0.113
1.507
-0.074

SE
0.155
4.638
0.260

p
0.464
0.745
0.776

c1
c2
c3

-0.138
-0.724
0.682

- 0.110
-2.477
0.130

0.042
0.862
0.050

0.009*
0.004*
0.009*

B

0.002

0.001

0.041

0.971
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Discussion and Conclusion
We have presented a nested case-control study that sought to examine the
effects of intraoperative hyperoxia on the occurrence of delirium. We found a
significant direct effect between the interaction of baseline neurocognition and
hyperoxia, and the odds of developing delirium. We, however, did not find a
significant mediating role of neuroinflammatory biomarkers measured in our
study. The causal effect of perioperative oxygen treatment on the occurrence of
delirium, however small the effect size may be, reechoes the fact that delirium is
etiologically heterogenous with likely many other possible pathomechanistic
pathways besides our observation. Despite the paucity of literature on the
relationship between perioperative hyperoxia and post-operative delirium, result
of our study is consistent with recent studies investigating the matter [190, 213].

In one of the aforementioned studies, Lopez, Pandharipande [190] monitored the
duration of cerebral hyperoxia with oximetry monitors intraoperatively and found
that despite the considerable fluctuations in cerebral oxygenation, hyperoxia after
a period of hypoxia was most strongly associated with the occurrence of delirium.
Authors also observed that in delirium subjects, there was an increase in plasma
concentrations of markers of oxidative stress (F2-isoprostanes and isofurans),
suggesting a possible mediation role. In the remaining study, Kupiec, Adamik
[213] established a maximum PaO2 cut-off of 33.2 kPa, beyond which postoperative delirium was more likely to occur. Notable differences between these
studies and ours is the relatively smaller sample size in our study, choice of the
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baseline neurocognitive assessment tool and the frequency of assessments for
post-operative delirium.

Traditionally, ascertaining the mediation effect of a variable M (e.g., biomarker
levels) on the relationship between a predictor X (e.g., baseline neurocognition)
and outcome Y (delirium) has required that a relationship already exists between
X and Y. This approach is heavily debated, and proposed alternatives suggest
that a prior relationship between X and Y, or the lack thereof, neither proves nor
rules out causal associations [214-216]. This was the observation in our study, in
which we found that the relationship between X and Y is moderated by the
interaction of another variable W (intra-operative oxygen therapy).

The clinical significance of the post-bypass increases in S100B levels without
any significant associations with delirium remains to be determined. This is also
the observation by Jönsson, Johnsson [217] and Nguyen, Huyghens [218]. Aptly
described by authors as the “controversial significance of early S100B levels
after cardiac surgery”, Jönsson, Johnsson [217] measured S100B levels at
defined intervals from end of bypass until 48 hours post-surgery, and concluded
that the predictive significance of the S100B biomarker is limited [217]. These
findings are in sharp contrast to many other studies in which S100B levels were
consistently increased in delirium cases regardless of the sampling time after
surgery [219-221]. These conflicting findings about the S100B-delirium
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relationship highlights three possibilities: (1) that plasma levels of S100B do not
necessarily reflect CSF levels, (2) the relatively short half-life of S100B (60 to 120
mins) requires that blood sampling is appropriately timed, or (3) that increases in
S100B levels only signal neuronal response to the surgical insult, and not
because of the occurrence of delirium. With regards to the gap in plasma-to-CSF
levels, S100B is also secreted by extra-neuronal tissues (e.g., adipocytes) [222,
223], although the predominant source remains in mature, perivascular
astrocytes [224, 225]. To ascertain that the post-bypass increases in S100B
levels in our cohort were not confounded by body fat, we performed stratified
analyses and found no differences in S100B levels by sex or by BMI.

Further, although there was no association between CPB duration and incidence
of delirium, we observe a downtrend in the absolute change in S100B levels with
increasing CPB times and found no significant change in S100B levels for
subjects with the longest CPB times (> 141 mins). We intimate that this is likely
due to the short half-life of the S100B protein, although this hypothesis will
require a formal interrogation from further studies.

Our study is, however, without limitations, notable among them is sample size
and selection bias. Our relatively small sample size (n = 46) did not allow for the
statistical adjustment of covariates such as age, sex, BMI in the structural
modeling and mediation analyses. Instead, we used stepwise regression to
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select the subset of variables with significant association to delirium in our cohort.
Moreover, we also controlled for possible confounding during the study designing
by matching cases to controls by age, sex, BMI and race (Table 3.1), and do not
expect the lack of statistical adjustments to have any significant impact on the
strength of associations in our findings. To prevent selection bias, subjects in the
present study were selected to reflect the distribution of treatment (hyperoxia
versus normoxia) and outcome (delirium case versus non-delirium control) in the
parent trial. We acknowledge that our cohort had considerable deficits in
neurocognition at baseline. While the ideal choice of controls would be subjects
without any baseline deficits, controls are more appropriately sampled from, and
in terms of risk, should be representative of the very population that gave rise to
the cases being investigated [226, 227]. Nonetheless, we excluded subjects with
extremely low tMoCA scores (< 10). In addition, patients’ baseline tMoCA scores
were included, and statistically adjusted for, in our models.

There are several mechanisms proposed to underlie the possible neurological
damage after cardiac surgery on CPB [228]. In our study, we focused on the
neuroinflammatory mechanism as a possible mediator of the exposure-tooutcome relationship. It is likely that our choice of biomarkers, albeit their
recognized associations with neuroinflammation, may not be directly involved in
the pathogenesis of post-bypass delirium. Given the half-lives and turnover of
many inflammatory proteins, it is equally likely that our timing of blood sampling
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did not permit detection of biomarker level that accurately reflects any possible
neuroinflammatory process that may have been at play.

To date, our study remains the only one that has investigated the effects of
perioperative hyperoxia on both the immediate and long-term neurocognitive
functions [188] in the same cohort of patients. Taken together, the findings that
hyperoxia increases the risk of post-operative delirium, yet with no association
with long-term cognitive decline, may best be explained by a dose-response-time
relationship, although further studies are required to definitely interrogate these
hypotheses.
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Abstract
Purpose
Delirium presents a significant healthcare burden. It complicates post-operative
care in up to 50% of cardiac surgical patients with worse hospital outcomes,
longer hospital stays and higher overall cost of care. Moreover, the nature of
delirium following cardiac surgery with cardiopulmonary bypass (CPB) remains
unclear, the underlying pathobiology is poorly understood, status quo diagnostic
methods are subjective, and diagnostic biomarkers are currently lacking.
Objective
To identify diagnostic biomarkers of delirium and for insights into possible
neuronal pathomechanisms.
Experimental design
Comparative proteomic analyses were performed on plasma samples from a
nested matched cohort of patients who underwent cardiac surgery on CPB. A
targeted proteomics strategy was used for validation in an independent set of
samples. Biomarkers were assessed for biological functions and diagnostic
accuracy.
Results
47% of subjects demonstrated delirium. Of 3803 total proteins identified and
quantified from patient plasma samples by multiplexed quantitative proteomics,
16 were identified as signatures of exposure to CPB, and 11 biomarkers
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distinguished delirium cases from non-cases (AuROC = 93%). Notable among
these biomarkers are C-reactive protein, serum amyloid A-1 and cathepsin-B.
Conclusions and clinical relevance
The interplay of systemic and central inflammatory markers shed new light on
delirium pathogenesis. This work suggests that accurate identification of cases
may be achievable using a panel of biomarkers.

Statement of Clinical Relevance
The acute implication of delirium is well-documented, yet the true extent of the
consequences beyond the immediate post-operative period has yet to be fully
known. Despite its impact on the geriatric population, delirium remains
underdiagnosed. Correctly identifying cases remain a challenge in clinical
practice: the arbitrary and subjective nature of current diagnostic tools, such as
the confusion assessment method, underscores the urgent need for diagnostic
biomarkers. The clinical usefulness of delirium biomarkers extent beyond the
objective identification of cases. Delirium biomarkers will also be useful for risk
stratification, long-term follow-up of patients and may offer insights into possible
etiologies that underpin the condition. In this report, we found systemic markers
of inflammation with well-established association with delirium, as well as new
biomarkers that shed new light on the condition. Although validation in a larger
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cohort is the necessary next step, our efforts lay the groundwork for future
studies and highlight new frontiers in delirium research yet to be explored.
Introduction
Delirium remains under-diagnosed in clinical practice[125, 229, 230].
Characterized by acute fluctuations in consciousness, deficits in attention and
impairments in cognition not explained by a pre-existing neurocognitive disorder,
delirium is etiologically heterogenous with a particularly high incidence after
cardiac surgery[154, 231]. Following cardiac surgery, it complicates postoperative care in up to 50% of patients with increased length of hospitalization,
increased mortality and higher overall cost of care[232]. In the long term, postcardiotomy delirium patients are at increased risk of many complications,
including re-admissions [233], cognitive decline [176, 234-236], functional
impairments [114], and stroke [237, 238], to mention a few. Clearly, delirium
presents a significant healthcare burden on society. The true extent of the
consequences beyond the immediate post-operative period remains unknown.
Thus, the accurate identification of subjects for optimal care in the immediate
post-operative period and for long-term follow-up is likely to exert a significant
positive impact on patient care and costs if implemented successfully.

Unfortunately, many patients with delirium are missed [126, 239], an observation
that is partly due to the subjective and variable nature of the current diagnostic
approach. Efforts to improve recognition and accurate case identification has
seen a steady rise in recent years, although a small fraction of these attempts
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has focused on biomarker discovery. Most of these biomarker studies also
employed targeted quantification strategies for a sub selected list of genes or
proteins, an approach that is inherently biased and blinded to potentially novel
factors involved in the etiology or consequences of delirium [130][submitted
manuscript].

Challenges with delirium biomarker discovery are due, in part, to the lack of
clarity regarding the underlying pathophysiology of the condition. While a onesize-fits-all explanation of delirium may be oversimplified, neuroinflammation
induced by system-wide activation of an inflammatory cascade remains the
prevailing mechanistic hypothesis[160, 240]. This is supported by recent
untargeted and semi-targeted approaches that sought to study the proteome of
human biofluids[2-8, 78], although neuroendocrine and circadian dysregulation
have also been reported[160]. The emerging focus on signaling and inflammatory
markers necessitate biomarker discovery approaches that focus on the lowabundance proteome, using analytical platforms with the multiplexing capability
and the requisite sensitivity to detect small changes in proteomic signatures.

In the present work, we comprehensively profiled the plasma proteome of
subjects at baseline and post-cardiotomy for an untargeted analysis of the
plasma proteome. We included abundant protein immunodepletion and peptide
fractionation to enhance signal from the low abundance plasma proteome. Using
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independent set of samples, we validated candidate biomarkers at three time
points (at baseline, post-bypass and post-operative) in order to understand the
changing trajectories of these biomarkers over time as they relate to case
identification. Finally, we demonstrate the diagnostic potential of a panel of
candidate biomarkers, the accuracy of their use in discriminating cases from noncases and the temporal association between intra-operative events and changes
in biomarker levels.

Materials and Methods
Study Design and Patient Enrollment:
Subjects in this nested case-control study were selected from the parent study, a
randomized double-blind trial conducted on subjects who underwent coronary
artery bypass grafting (CABG) with cardiopulmonary bypass (CPB) between July
2015 and July 2017 at the Beth Israel Deaconess Medical Center (BIDMC) in
Boston MA. The trial was registered with ClinicalTrials.gov (NCT02591589,
https://clinicaltrials. gov/ct2/show/NCT02591589, principal investigator: Shahzad
Shaefi, registration date: October 29, 2015). Institutional review board (IRB)
approval 2014P000398/33 was amended for the purposes of this current study
on 09/17/2021 by the Committee on Clinical Investigations at the BIDMC. Details
of enrollment, subject randomization and treatment allocation in the parent study
are published elsewhere [188, 209]. Briefly, patients aged 65 years or older who
were booked for elective CABG requiring CPB were eligible. The primary
objective was to examine the temporal relationship between intra-operative
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oxygen treatment and post-operative neurocognitive function as measured by the
telephone-based Montreal Cognitive Assessment (tMOCA) score. Patients were
assessed for delirium as a secondary endpoint using the confusion assessment
method (CAM). Patients were excluded if they were undergoing emergent CABG,
if they required single-lung ventilation, CABG without CPB, intraoperative balloon
counter-pulsation or mechanical circulatory support. All patients provide informed
consent. 15 subjects were randomly selected for proteomic profiling in this
nested case-control study. Because quantitative studies on the effect size of
delirium biomarkers using mass spectrometry is largely unexplored, formal power
analysis was not done.

Sample Collection:
Whole blood samples at baseline, post-bypass (P-BP) and on post-operative day
one (PO1) were collected into 4mL EDTA-treated tubes (BD Diagnostics) and
centrifuged immediately at 200g at room temperature for 10 min. Resulting
plasma was stored at -80ºC until they were thawed for aliquots used here for
proteomic profiling.

Chemicals and Reagents:
All LC-grade chemicals are marked with asterisk (*): Dithiothreitol (DTT), 4-(2hydroxyethyl)-1-piperazineethanesulfonic acid (EPPS), Tris (hydroxymethyl)
aminomethane (Tris), formic acid* and acetonitrile* were purchased from Sigma88

Aldrich. Methanol* was obtained from Fisher. Trypsin Protease, SDS, 2iodoacetamide (IAA), High Select Top14 Abundant Protein Depletion Mini Spin
Columns and TMT 11 plex kit were acquired from Thermo Fisher Scientific.

Sample Preparation analysis:
Sample Immunodepletion:
Buffer exchange on single-use High Select Top14 Abundant Protein Depletion
mini-spin columns (ThermoFisher Scientific) was performed twice using 200 µL
of 50mM Tris [pH 8.1] / 50mM NaCl. 10 µL of each plasma sample was applied
to the mini-columns, incubated at -4ºC with gentle end-over-end mixing for 15
min, according to manufacturer’s instructions. Flowthrough were collected by
centrifugation at 1000g for 2 min into 2mL Eppendorf tubes. Concentrations of
the depleted samples were obtained using the Pierce BCA Protein Assay Kit
(Thermo Scientific) at 562 nm absorbance per manufacturer’s instructions.

Expression and purification of recombinant CDS1 protein:
A CDS1 G-block was purchased from IDT and cloned into the pET16b plasmid. A
pET13S-A plasmid containing λ-phosphatase was purchased from Addgene.
CDS1 and λ-phosphatase were co-transformed with into BL-21 Rosetta E. Coli
and colonies were grown in 5 mL LB medium (BD) with no antibiotic at 37°C
overnight. The 5 mL culture was added to 400 mL LB medium with no antibiotic
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and grown at 37°C until it reached an OD600 of 1. The temperature was
decreased to 10°C and IPTG (UBP Bio) was added to a final concentration of 1
mM to induce CDS1 and λ-phosphatase expression. The presence of λphosphatase was necessary to solubilize CDS1. The culture was incubated for
24 hours before collection. Cells were frozen at -80°C in batches of 50 mL until
purification.

To purify CDS1, cells were lysed in buffer (50 mM Tris pH 7.5 (Fisher Scientific),
10 mM imidazole (Fisher Scientific), 150 mM NaCl (Fisher Scientific), 1% TritonX 100 (Sigma), 0.1 mM DTT (Amresco), and 1:500 protease inhibitor cocktail III
(Research Products International)), sonicated, clarified by centrifugation, and
incubated with Ni-NTA beads (Qiagen) for 3 hours at 4°C. Beads were collected,
washed, and CDS1 eluted at room temperature in elution buffer (50 mM Tris-HCl
pH 8.0 (Fisher Scientific) and 1 M imidazole (Fisher Scientific)). CDS1 was
dialyzed overnight into dialysis buffer (25 mM Tris pH 7.5 (Fisher Scientific), 50
mM NaCl (Fisher Scientific), and 0.1 mM DTT (Amresco)), aliquoted, and stored
at -80 °C. Purified CDS1 was separated on an SDS-PAGE, Coomassie stained,
visualized using a BioRad Gel Doc EZ imager, and quantified against a BSA
standard using BioRad Image Lab 6.1 software.
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Digestion and Labelling for Biomarker Discovery
Depleted samples were treated with SDS (2% final) and DTT (2mM final) for
denaturing at 75ºC for 15 min. Samples were cooled to room temperature before
alkylation with IAA (7mM final) at room temperature in darkness for 30 min and
quenched with DTT (additional 2mM final) for 10 minutes. Proteins were isolated
by single-pot solid-phase-enhanced sample preparation (SP3) and digested to
peptides in EPPS buffer overnight at 30ºC with 1:50 w/w trypsin (PromegaTM).
Tryptic peptides were labeled with TMT-11 plex reagent for 1 hr according to
manufacturer’s instructions. Two channels in each set of TMT-11 plex were
reserved for pooled plasma to be used as bridge samples for technical control.
Labeling efficiency of at least 95% was confirmed on a 1-hr gradient before
pooling. Labeled tryptic peptides were then desalted on an OASIS µHLB
(Waters) and subsequently dried by vacuum centrifugation prior to off-line HPLC
fractionation on a pentafluorophenyl (PFP) column as described previously [62].
48 fractions were concatenated into 12 fractions for LC-MS/MS analysis. All
samples were prepared in duplicates.

Digestion for Biomarker Validation
Equal amounts of recombinant purified CDS1 protein were added to each
depleted sample before treatment with SDS (2% final) and DTT (2mM final) for
denaturation and alkylation as described above. Proteins were isolated by singlepot solid-phase-enhanced sample preparation (SP3) and digested to peptides in
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50mM ammonium bicarbonate buffer overnight at 30ºC with 1:50 w/w trypsin
(PromegaTM). In a separate experiment to check for signal linearity, increasing
concentrations of heavy-labeled peptides of CNDH2 condensin subunit were
added to the samples at this point. Tryptic peptides were desalted on an OASIS
µHLB (Waters) and dried by vacuum centrifugation. All samples were run in
duplicates.

LC-MS/MS
All data were acquired on an Orbitrap Fusion Lumos Tribrid instrument
(ThermoFisher Scientific, San Jose, CA) equipped with EASY-nanoLC 1200
ultra-high pressure liquid chromatograph (ThermoFisher Scientific, Waltham,
MA). Dried peptides were resuspended in 5% methanol / 1.5% formic acid and
injected onto a 35-cm long / 100-µm (inner diameter) in-house pulled analytical
column packed with Reprosil C18 stationary phase particles. Discovery samples
were separated on 120-minute gradient, and validation samples on a 60-min
gradient, at 350nL/min flow rate. Acquisition parameters included 120,000resolution at MS1, AGC target value of 5.0×105, scan range of 350 – 1250 m/z
and maximum injection time of 100ms. For the TMT-labeled peptides, the top
eight MS2 peaks were selected for further fragmentation at 55% normalized highcollision energy (HCD) via SPS-MS3 for quantification of reporter ions in the scan
range of 110 – 500 m/z. For the label-free peptides in the validation phase, MS2
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scans were generated at 30,000 resolution and AGC value of 2.5×105, using
30% normalized collision energy (HCD).

Bioinformatics
Peptide Spectral Matching:
Acquired data (in .raw format) were searched using COMET [95] against a
target-decoy version of the human proteome (Uniprot, downloaded in 2020 and
2022, for the discovery and validation phases respectively). The fasta for the
validation phase was appended with sequences from CDS1_SCHPO. Search
parameters included a mass tolerance of 20ppm, maximum missed cleavages of
3, carbamidomethylation of cysteine as fixed modification and oxidized
methionine as variable modification. In addition, the mass of 229.162932 Da was
added to the N-termini and lysine residues of all peptides as fixed modification for
the TMT data. A false discovery rate (FDR) of 1% was applied at the peptide
level and final list of PSMs were filtered using XCorr and delta XCorr. All data
were subsequently imported into R environment for statistical computing (v4.1.1)
and Python programing language (v3.8) for downstream analyses [212, 241].

TMT Data Wrangling and Normalization (Discovery Phase):
After correcting for differential sample loading, the ratios of sample proteins to
their respective bridge proteins were computed. Here, data from bridge samples
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was used for quality control and to correct for batch-to-batch technical variations.
Values were subsequently log-transformed and mean-centered. Data from all
batches were combined and analyzed for possible outlier observations using
OutlierDM R Package. Proteins were removed if their frequency of observation
was less than half of all samples. For one-hit wonders in each batch of
experiment, a retention time (RT) predicting model was built in Python using
DeepRT+ as described by Ma, Ren [242]. Prediction performance was assessed
with coefficient of determination (R2) and delta-t95% (∆t95%). ∆t95% is the minimum
time window containing deviations between the observed and the predicted RT
for 95% of the peptides. Peptides with RT outside the ∆t95% range were excluded
from downstream analysis. Missing entries in the data were imputed by making
random draws from the left tail of the gaussian distribution of the entire logtransformed data matrix (using -2.5 SDs from the mean, width = 0.3).

Protein Feature Selection and Differential Abundance Analyses
To determine the subset of protein features that differentiated cases from noncases, or postoperative expression profiles from baseline, Elastic Net algorithm
was used [243]. This is a regularization and feature selection method with good
performance on high-dimensional data (i.e., an n×p data with very large p
proteins but small n samples). Elastic Net is insensitive to features that dominate
the matrix (e.g., albumin) and likely suppress signal from low abundance
predictors and skew model coefficients. In addition, Elastic Net is a good choice if
overfitting and multicollinearity (or protein features that are highly correlated and
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essentially communicate the same information) are a concern. Tuning
parameters were achieved by grid optimization with a five-fold nested crossvalidation where the last fold was held out for testing. The average of
hyperparameters from all folds were computed and used to build the final model.

Using the subset of protein features, an unsupervised visualization of the data
was achieved with principal component analysis (PCA). Hierarchical clustering
was employed to check for reproducibility of replicate samples and inherent
sample clusters, and together with a heatmap, the overall protein expression
patterns. Here, clustering was achieved using Ward’s clustering algorithm.[244]
Briefly, Ward’s minimum variance method begins with singleton clusters and
recursively merges them by minimizing the total within-cluster variance as the
objective function. After this point, protein values for any given biological
replicates were summarized as means prior to differential abundance analyses.
Two-way comparison for differential abundance was achieved by Student’s t-test,
assuming unequal variance. Differential abundance analysis was visualized with
volcano plots. Because statistical comparison was done for only a subset of
proteins, no correction for multiple hypothesis testing was done. Proteins were
deemed differentially regulated between conditions if there was a statistically
significant t-test (p value cutoff ≤ 0.05) and a log2 fold-change of at least ±1. This
fold-change cutoff was selected to prioritize a panel of biomarkers with significant
changes between conditions that is unlikely to be due to chance.
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PRM Label-free Data Procession (Validation Phase):
Raw files were imported into Skyline v21.2.0.369 [103]. Precursor peptides with
modifications other than carbamidomethylation of cysteine (as fixed modification)
or oxidized methionine (as variable modification) were excluded. Peptide
quantification criteria was defined as follows: (1) consistently identified
precursors across all validation samples, (2) with maximum of two missed
cleavages, (3) a consistent minimum of five transitions, and (4) at least 0.95 dopproduct with the spectral library of chromatograms. All peak boundaries were
manually inspected for interference-free co-eluting transitions before peak areas
were integrated at the MS2 level. For any given precursor peptide, the five most
intense fragment ions in the m/z range of 120 – 1500 were used for
quantification. Final dataset was exported as .csv and analyzed in R environment
for statistical computing (v4.1.2; R Core Team 2021). No imputations were
required in the validation data. Data was normalized by computing peak area
ratios relative to CDS1_SCHPO to correct for run-to-run variations. For each
protein biomarker, Kruskal Willis global test was first used followed by post-hoc
Mann-Whitney U test for pairwise comparisons of the normalized peak areas
between the different sample collection timepoints (baseline, post-bypass and
post-operative day 1).

Data accessibility statement:
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Datasets from the discovery and validation phases are available as supplemental
material.

Results
Clinical Profile of Study Participants
Subjects (n = 15) were selected from the parent study[188], which was a parallel
group randomized controlled trial that enrolled 100 patients at Beth Israel
Deaconess Medical Center (BIDMC), between July 2015 and July 2017. Delirium
cases and non-delirium controls were age- and sex-matched (Table 1). There
was no difference in baseline neurocognition between cases and non-cases, and
the proportion of patients who received hyperoxic intraoperative treatment was
comparable. There were no significant differences with regards to demographics,
medical co-morbidities, pre-operative medications, or surgical characteristics.
Details of the clinical characteristics of study subjects were reported
previously[188].
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Table 4. 1 Selected baseline characteristics of study subject in the discovery
phase
Delirium Cases
Non-Delirium Controls
Sample
n=7
n=8
Age
70 (±5.0)
71 (±4.4)
Sex (male)
7 (100%)
8 (100%)
tMOCA
17 (±2.3)
17 (±1.9)
Hyperoxia
4 (57%)
4 (50%)
tMOCA: telephone-based Montreal Cognitive Assessment test for Dementia

98

Discovery Phase of Biomarker Workflow
Using a multiplexed isobaric tagging (TMT)-based design, plasma samples at
baseline and on post-operative day 1 from 7 delirium cases (CAM+) and 8 nondelirium controls (CAM-) were comprehensively profiled (Figure 4.1). For
precision, samples selected for the discovery phase of the study were analyzed
in duplicates, for a total n = 60 samples, which necessitated the analysis of seven
separate, batched multiplexes. To control for technical variation between
batches, two channels in each of the seven 11-plex TMT sets were reserved as
bridge samples using equal amounts of a pooled plasma sample. We
fractionated the TMT-labeled peptides using off-line HPLC on a
pentafluorophenyl (PFP) column as described previously[62] into 48 fractions,
which were subsequently concatenated into 12 and analyzed by LC-MS/MS on
an Orbitrap Fusion Lumos Tribrid instrument platform.

A collective total of 17,540 unique peptides from 3,803 proteins were identified
from all seven multiplexes. An analysis of the number of proteins from each
batch, separated into a binary group based on the corresponding number of
peptides used in the identification of these proteins, demonstrates that our data
are clearly dominated by so-called “one-hit proteins,” or proteins identified by a
single peptide (Figure 4.2A). Often, single-peptide protein identifications are
excluded from downstream analysis due to the increased risk of false protein
identifications associated with single-peptide protein assignments. However,
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Figure 4. 1 Study Design and Biomarker Discovery Workflow
Biomarker discovery: a cohort of 15 subjects were selected from the parent study
of 100 patients who underwent a non-emergent coronary artery bypass grafting
(CABG) on cardio-pulmonary bypass (CPB) as part of a previously published
clinical trial (1,2). Plasma samples of delirium cases (CAM+) and non-delirium
controls (CAM-) were retrieved from the biorepository for subsequent proteomic
analysis (3). Samples were immunodepleted, digested and labeled with multiplex
isobaric quantification (TMT) reagents. For each set of TMT reagents, two
channels were reserved for bridge samples for post-hoc batch correction (4).
TMT-labeled samples were concatenated (5) and additionally fractionated (6)
prior to LC-MS/MS (7) for quantification at MS3 (8). After peptide spectral
matching and false discovery rate (FDR) curation, the final dataset of 3803
proteins was quantified and analyzed for candidate biomarkers (9).
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excluding all one-hit proteins can be a huge informational cost as some of these
proteins may be biomarkers of interest.

One-hit Proteins and Deep Learning for Confident Protein Identification:
To examine this further, we differentiated one-hit proteins identified only in single
batches of experiments from those identified consistently across multiple
batches. We reasoned that identified one-hit proteins consistently identified in
multiple independent analyses are less likely to be false identifications, especially
if their consistent identification is based on the same unique peptide. These onehit proteins warrant additional peptide-centric information for protein inference
beyond the sequences of the single peptides. Figure 4.2B displays the number
of proteins identified in any given number of collective batches. Of the 3803 total
proteins (figure 4.2B, cumulative batch ≤7), 51% (n = 1941 proteins) were
identified based on a single peptide. While the number of proteins identified
based on 2 or more peptides increased with increasing number of collective
batches, the number of one-hit proteins remained fairly consistent. In particular
for cumulative batches three to seven, we found 1698 one-hit proteins that were
present in all of them.
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To enhance the confidence in the identity of these one-hit proteins and minimize
false positive identifications, we employed chromatographic retention time (RT)
as additional peptide-centric information and orthogonal to their identification by
tandem mass spectrometry. Here, we considered a peptide as confidently
identified if, in addition to being a high-scoring peptide by PSM, the observed RT
also falls within the RT window expected for that peptide and its corresponding
experimental batch conditions.

For example, K.GTEAAGAMFLEAIPMSIPPEVK.F , a unique peptide from alpha1-antitrypsin, A1AT_HUMAN (figure 4.2C, supplemental figure 4.1, blue
rectangles) shows consistent RTs, regardless of the experimental batch or
sample fraction the peptide was detected. On the other hand,
K.GTEDFIVESLDASFR.Y (figure 4.2C, supplemental figure 1, red rectangles)
is the only peptide-evidence that translocon-associated protein subunit alpha,
SSRA_HUMAN – a one-hit protein – was detected in experimental batch 2.
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Figure 4. 2: Data preparation for downstream analyses
A: Total number of proteins identified per batch. Bars are demarcated by the
number of unique peptides used for protein identification. Gray portion of each
bar chart represents proteins identified by only a single peptide, highlighting the
scope of one-hit proteins in our analysis. B: Number of proteins identified in a
cumulative number of experimental batches. For example, of the 1638 total
proteins identified in up to two cumulative batches of experiments (cumulative
batch ≤ 2), about 90% of those (n = 1470) were one-hit proteins. The number of
one-hit proteins increases only marginally with increasing cumulative batches
(light green portion of the green bars), in contrast to proteins identified from at
least two peptides. C: Chromatographic retention times of select peptides from
the discovery experiment. Plot shows the consistency of retention times (RT) of
K.GTEAAGAMFLEAIPMSIPPEVK.F (blue rectangle), observed in two fractions
from multiple LC-MS runs. K.GTEDFIVESLDASFR.Y (red rectangle), on the
other hand, was only identified once. In the absence of additional peptides, these
single peptides required further information to reduce false protein assignments.
D: Scatter plot of experimental and predicted RTs of peptides from experimental
batch 1. RTs were predicted by training a deep learning RT predictor, DeepRT+.
Prediction performance is assessed with R2 and ∆t95% (red dashed lines). up =
number of unique peptides trained. E: Selection of the final 1731 proteins for
downstream differential abundance analysis. Use of DeepRT+ salvaged 495 onehit proteins that would otherwise be removed from downstream analysis. F:
Dynamic range of all 1731 proteins, ranked in decreasing order of intensity. Each
dot represents the median intensity of all intensity values recorded for a given
protein across all samples. Intensity is plotted on the log-scale and spans 6.3
orders of magnitude between the high-abundance classical plasma proteins and
the low-abundance signaling proteins. Functional groups are based on Putnam's
classification. Red dots highlight representative members in each functional
group. Labels are gene names of the corresponding proteins
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To determine the RT window expected for these single peptides given the LC-MS
conditions of their respective experimental batches, we trained a deep learningbased RT predictor, the DeepRT+ [242], using 80% of the RT of consistently
identified peptides for a given experimental batch. We tested the prediction
accuracy of the DeepRT+ model with the remaining 20% of the training data and
subsequently used the final model to predict the RT of one-hit proteins.

We assessed performance of the RT prediction using the coefficient of
determination, R2, and ∆t95%, the minimum time window containing deviations
between the observed and the predicted RT for 95% of the peptides (Figure
4.2D and Supplemental Figure 4.2). We found the RT of 495 unique one-hit
peptides fell within the ∆t95% metric (Table 2) and were thus included to a final
total of 1731 proteins used for downstream analysis (Figure 4.2E). The dynamic
range of all proteins spans 6.3 orders of magnitude and confirms signal from a
wide range of abundances in the plasma proteome (Figure 4.2F).
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Table 4. 2 Summary of DeepRT+ training parameters and results of prediction
assessment.
Training Parameters
Results
2
Batch RT
RT
max
up
up
∆t95% R
Eliminated
(min) (max) aa
(training) (predicted)
length
1
4.1
129.2 46
8414
776
6.89
0.989 145
2
5.2
129.4 45
8327
758
7.95
0.986 104
3
10.2 129.7 44
9240
859
12.35 0.973 127
4
9.3
129.5 43
7589
646
9.67
0.988 121
5
10.5 128.7 40
7207
749
11.24 0.975 129
6
4.4
128.6 43
10829
849
6.22
0.991 170
7
11.1 128.7 42
6406
734
9.45
0.982 120
Training. Given that each batch of sample has unique LC-MS experimental
conditions that uniquely impact RT, seven different models were built for each of
the seven batches of experiments. Abbreviations: RT (min): minimum RT for the
batch; RT (max): maximum RT; aa: amino acid; up (training): number of unique
peptides trained; up (predicted): number of unique peptides whose RTs were
predicted; R2: coefficient of determination = correlation coefficient for bivariate
analysis; ∆t95%: deviations between observed and predicted RT that contains
95% of peptides for a given batch of experiment.
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Protein Feature Selection and Differential Abundance Analyses
To determine the subset of these 1731 proteins that are most important in
discriminating plasma profiles of cases and from non-cases and between
baseline and post-operative timepoints, we employed an elastic net regularized
regression approach[243]. We found 47 and 64 proteins as signatures of surgical
exposure and of delirium, respectively. Principal component analysis (PCA) of
study subjects using the subset of protein features demonstrates that delirium
cases cluster separately, with marginal overlap between non-delirium controls
and baseline samples (Figure 4.3A). Additionally, plasma profiles of cases and
non-cases are clearly separable post-operatively, although they were
indistinguishable at baseline (Figure 4.3B). This strongly suggests a temporal
relationship between post-operative changes in proteomic signatures and
subjects’ surgical exposure and/or related intra-operative physiological events.

Furthermore, we quantified the extent of changes in biomarker levels before and
after surgery (Figure 4.3C) and between cases and non-cases (Figure 4.3D).
When using the proteins identified as a signature of delirium (Figure 4.3D), we
observed a
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Figure 4. 3 Clustering, differential abundance and functional analyses
A: Principal component analysis of all discovery samples (including replicates).
Clustering is based on a subset of 64 proteins identified by the penalized
regression approach (ElasticNet) for feature selection. B: Hierarchically clustered
heatmap of proteomic signatures of delirium cases and non-delirium controls at
two time points (baseline and post-operative day 1, PO1). Post-operatively, a
subset of proteins (protein cluster 2, dashed lines) shows a higher expression in
cases relative to non-cases, although the expression of this subset of proteins
was very similar between the two groups at baseline. C: Volcano plot of p-value
(log10 scale) vs fold-change (log2 scale) of the 47 proteins that explain most of
the variation in proteomic profiles of the baseline and post-operative day 1
samples. Blue dot means protein is significantly different at PO1 relative to
baseline by at least 2 folds (p-value cut-off = 0.05). D: Volcano plot of the 64
proteins that explain most of the variation in proteomic profiles between delirium
cases and non-delirium controls. E: Diagnostic accuracy of the panel of 11
differentially abundant proteins that discriminate cases from non-cases. F:
Functional analysis of biomarkers for biological processes enriched among the
panel of 11 differentially abundant proteins that discriminate cases from noncases.
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diagnostic accuracy of 93% in discriminating cases from non-cases (Figure
4.3E). Functional analysis of the biomarker panel for biological processes shows
acute inflammatory response and activation of the immune system as the most
significantly enriched functional pathways, predominantly in the extracellular
region (Figure 4.3F and Supplemental Figure 4.3).

Biomarker Verification
For further evaluation of peri-operative proteomic differences between cases and
non-cases, an independent set of plasma samples was used to verify biomarkers
discovered a priori (Figure 4.4). Here, we used parallel reaction monitoring
(PRM) as the targeted approach and employed label-free quantification (LFQ) as
orthogonal methods different from the TMT approach used in the discovery
phase. To ascertain the degree to which changes in protein concentration in the
complex background of plasma are quantifiable, we artificially modified six
biological replicates of a pooled plasma sample with the addition of exogenous
proteins: (1) equal amounts of a non-human (Schizosaccharomyces pombe)
homolog of the serine/threonine-protein kinase Chk2 (CDS1 in S. pombe); and
(2) increasing concentrations of heavy-labeled AQUA peptides[245, 246] of
human condensin-2 complex subunit H2 (CNDH2). From this experiment, we
estimate a limit of quantification of ~1fmol on column (Figure 4.5A), with
negligible impact on target protein quantification due to matrix effects from large
(16-fold) variations in the concentration of a non-target protein in the matrix
(Supplemental Figure 4.4).
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Figure 4. 4 Biomarker Validation
Validation samples included baseline (B), post-bypass (P-BP) and post-operative
day 1 (PO1) samples. To each unlabeled validation sample, an equimolar
amount of CDS1, a protein from S. pombe with no sequence overlap to human
proteins previously expressed and purified from bacteria, was added as a
reference standard to control for run-to-run variations. Select tryptic peptides of
regulated proteins from the discovery phase were targeted for quantification
using via PRM-MS. Concentrations of each biomarker were analyzed for
changes across the sampling time points (B, PB, PO1). Hypothetical data are
depicted as exemplars.
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For candidate biomarker verification, we developed parallel reaction monitoring
(PRM) methods through an iterative optimization process (Supplemental Figure
4.5). We monitored 153 unique peptide sequences (212 total precursor ions
including the observed range of charge states) from the union of 18 differentially
abundant proteins as PRMs that were distributed across the entire LC-PRM
elution gradient (Figure 4.5B). For example, we monitored the abundance of the
peptide ESDTSYVSLK from C-reactive protein as a doubly charged ion via five
individual y-ions in our PRM method via Skyline (Figure 4.5C) in each
verification sample. The PRM methods we employed required the following
minimum criteria for peptide quantification: a consistent minimum

of 5 transitions in all samples, a minimum dot-product of 95% and manual
inspection of all peaks for interference-free co-eluting transitions with distinct
peak boundaries. 65 precursors from 13 proteins met these criteria for
downstream analysis (Supplemental Table 4.3). Unsupervised clustering based
on the quantification of these candidate biomarkers shows that post-operative
samples aggregate separately from post-bypass and baseline samples (Figure
5D). This is further confirmed by statistical comparison of biomarker levels
between the sampling timepoints (Figure 4.5E and Supplemental Figure 4.6).

Seven biomarkers (A2GL, AACT, CH3L1, CRP, LBP, MA1A1 and SAA1/SAA2)
were significantly increased at post-operative day one (PO1) relative to baseline
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Figure 4. 5 Analyses of Validation Data
A: Normalized peak areas of CNDH2_HUMAN condensin subunit with increasing
concentrations of its heavy-labeled stable isotope standards spiked into a
background matrix of plasma. Grey area is the 95% confidence band of the
regression line of fit: y = (12.84 + 33.25x[CNDH2]) x 106. B: Number of
precursors monitored concurrently during five-minute windows across the 78minute gradient for used for validation experiments. C: Representative extracted
ion chromatogram (XIC): the five most intense fragment ions of the
CRP_HUMAN peptide ESDTSYVSLK, co-eluting at 28.3mins. All other peptides
were quantified similarly with a minimum of five transitions consistent across all
samples, a minimum dot product (dotp) of 95% and manual inspection for distinct
peak boundaries and interference-free transitions. D: Principal component
analysis of all validation samples. Notable here is the clustering of post-bypass
samples together with the baseline, signaling similar proteomic signatures
between the two timepoints. E: Representative plot of differential abundance
analysis of validated proteins for the candidate biomarker C-reactive protein
(CRP), showing changes across the three sample collection time points:
baseline, post-bypass (P-BP) and post-operative day one (PO1). F: ROC
analysis of the discriminatory power of the validated panel of biomarkers
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in this validation cohort. Four razor peptides were shared between SAA1 and
SAA2. However, no peptides unique to either SAA1 or SAA2 met the minimum
quantification criteria for PRM verification. Similarly, none of the precursor
peptides of CAH3, EFNA1, FGL1 or PEPA4 met PRM quantification criteria.
Regardless of statistical significance, we observe that these candidate biomarker
levels show a consistent increase in abundance between baseline and PO1
(Supplemental Table 4.3). This panel of differentially abundant candidate
biomarkers yields a discriminatory power of 96% (84.9 – 100%) between cases
and non-cases (Figure 4.5F).

Discussion
This unbiased proteomic analysis of samples from a prior nested case-control
study is the deepest unbiased plasma proteomic profiling for potential biomarkers
of delirium to date. We employed a rectangular biomarker workflow[30] to both
discover and verify biomarkers of post-operative delirium on a single mass
spectrometry platform without the use of traditional affinity-based verification
methods. Dominated by one-hit wonders, our focus on the low-abundance
proteome presented us with the challenge of protein inference, for which we
applied deep learning to recover pertinent orthogonal peptide chemical information
and salvage a significant number of these one-hit proteins.
We identified 3808 proteins by isobaric quantitative multiplexed proteomics, 16
of which were differentially abundant post-operatively from baseline levels, and
11 of which were differentially abundant in cases relative to controls. This
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includes proteins with well-documented associations with delirium, such as CRP,
CH3L1, AACT, TIMP1, as well as new ones not previously associated with
delirium, including SAA, CATB and PEPA3. Using an independent set of
samples, we attempted to verify the union of these candidate biomarkers and
found a 96% accuracy in correctly identifying delirium patients for those for which
quantification was possible. Collectively, our findings show a temporal
association between intra-operative events (i.e., surgical insult, administered
anesthesia, etc.) and proteomic changes associated with phenotypic delirium.

The prevailing mechanistic hypothesis of delirium is one of acute neurocognitive
disruption triggered by system-wide inflammation[160, 240]. In our study,
functional analysis of the post-operatively dysregulated biomarkers suggests a
system-wide activation of the inflammatory cascade and related immunological
reactions. Data on the associations between delirium and acute-phase reactants
(APR) such as CRP is ubiquitous[2, 171, 175, 247, 248]. Although known APRs
correlate well with the severity of inflammation, their usefulness as biomarkers is
limited as they are not specific to delirium. We, however, found additional acutephase reactants that may shed a new light on delirium.

Human serum amyloid A (SAA) is a collective name for a group of polymorphic
proteins functionally associated with high-density lipoprotein (HDL). By the
regulation of their synthesis, they are grouped into the acute phase isotypes (a-
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SAA: SAA1, SAA2 and SAA3) and the constitutive isotype (c-SAA: SAA4)[249,
250]. Although predominantly secreted by the liver, extra-hepatic production
occurs in the brain and may be more relevant in neurocognitive disorders such as
Alzheimer’s disease[251-254]. SAA has cytokine-like effects which likely provokes
blood brain barrier (BBB) dysfunction, induces depressive-like behavior in mice
and may impair cognition in human subjects[255-258]. In the present study, we
found SAA1 and SAA2 were both upregulated post-operatively in delirium cases
by over 5 folds (p value < 0.001). This is the first mention of SAA in the context of
delirium and warrants further studies to formally credential this association with the
condition.

The cysteine protease cathepsin B (CATB) has previously been quantified as an
AD-related biomarker and correlates with mini-mental state examination (MMSE)
scores [259-262], but its association with delirium is unknown. It is an
inflammasome that promotes IL-1beta maturation and secretion[262]. It also has a
beta-secretase activity, capable of cleaving amyloid precursor protein into amyloid
beta [263]. Given that cases and non-cases in our study were matched by baseline
neurocognition and tMOCA scores were statistically controlled for, upregulation of
CATB in delirium cases may indicate a common pathophysiological starting point
in the continuum of neurocognitive disorders, of which delirium and AD are a part.
Generally recognized as the first enzyme to be discovered, pepsin (PEP-A) is the
native acid protease of the stomach[264]. Blood pepsin is an established
biomarker of gastric mucosal integrity, and plasma levels correlate with the degree
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of mucosal damage[265-268]. Cardiac surgery and CPB places enormous
physiological stress on the body. Through the cholinergic anti-inflammatory reflex,
the body attempts to ameliorate the stress by increasing vagal tone[269-272] which
manifests as gastric acid production. Normally, small amounts of secreted pepsin
(~1%) may be found in blood and urine[273], but with increased acid production,
this proportion may be higher. In the discovery phase of our study, differentially
abundant PEP-A levels in cases relative to non-cases (1.64-fold increase, p value
< 0.001) despite pre-operative proton-pump inhibitor administration in the study
subjects suggests a peculiar association between plasma PEP-A levels and
delirium. At present, we are unable to explain the relationship, if any, between
increased vagal tone and neuroinflammation.

The independent association between CPB and delirium remains an ongoing
debate and data on the relationship is conflicting. On the one hand, the use and
duration of extracorporeal circulation is reported to increase the risk of
delirium[274-276]. Some authors, on the other hand, have reported no
associations between delirium incidence and CPD duration[277, 278]. In our
cohort, there was no statistically significant difference in aortic cross-clamp time or
duration of bypass between delirium cases and non-cases.[188] To determine the
impact of CPB in our cohort, we compared post-operative plasma profiles to
baseline regardless of the case/non-case status of subjects. We found 16
dysregulated proteins, most of which have been characterized as non-specific
markers of surgical exposure[145, 279, 280]. A striking observation in our study is
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the similarities in proteomic signatures between cases and non-cases at baseline,
despite a clear difference at post-operative day one. Previous studies have shown
that post-operative delirium cases are likely to be in a heightened pre-operative
inflammatory state [2, 247, 270, 281-284], which makes them more vulnerable to
intraoperative stressors. In our study, similarities in the levels of identified
biomarkers at baseline suggests otherwise.

The main strength of the present study is in its unbiased, hypothesis-generating
approach to identify potential biomarkers of delirium. This lays the groundwork
for future studies and highlights new frontiers in delirium research yet to be
explored. Translational utility from the research bench to the patients’ bedside
requires that the biomarker readout in the discovery phase is independent of the
measurement approach used for their discovery[285]. For this reason, we
validated discovered biomarkers using label-free quantification, which is
orthogonal to the TMT-based measurements in the discovery phase of our study.
Our choice of PRM-MS over traditional affinity methods for validation (e.g.,
ELISA) is further premised on the fact that affinity methods are semi-quantitative
with inter-operator variability in quantification, have limited dynamic range and
require larger amounts of sample. In addition to the requirement for peptide
antigenicity, antibody cross-reactivity limits multiplexing (i.e., how many proteins
can be validated at a time)[286]. All proteins needing validation require
antibodies, a step that takes considerable amount of time to develop and can be
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cost-prohibitive if commercial options are not available[69]. This, in fact, is a longstanding bottleneck in clinical biomarker workflow[287].

Our study is, however, not without limitations. First, sample sizes for both the
discovery and validation phases may have limited statistical power in detecting
differences in the levels of many other biomarkers. In our cohort, the CAM test was
administered daily after surgery. In our statistical analysis, we did not correct for
the effects of retesting on repeated test administration in this cohort. In the
discovery phase, our interest in the low-abundance plasma proteome required an
immunodepletion step to remove the majority of the top 14 most abundant plasma
proteins. The extent to which this experimental step contributed to the removal of
other proteins through their specific or non-specific binding was not ascertained.
Although isotypes SAA1 and SAA2 each had unique peptides in the discovery
phase, only the razor peptides met the criteria for quantification in the validation
phase and were thus undistinguishable. Similarly, peptides from CAH3, EFNA1
and PEPA3 did not meet the minimum quantification criteria for verification by
PRM, and peptides from FGL1 were not detected at all in any of the verification
samples by PRM.

In summary, diagnostic biomarkers of delirium are urgently needed for accurate
case identification, long-term risk stratification and for molecular characterization
of delirium. In this study, we discovered a panel of biomarkers through the
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unbiased comparative analyses of baseline and post-operative plasma samples
of delirium cases and non-cases. We underscored the importance of brainspecific biomarkers such as SAA and CATB and their possible role in the
pathophysiology of delirium. In the long-term, it is in our research interests to
rigorously test their associations with delirium and ascertain how these
biomarkers change over time in a larger independent cohort.
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Supplemental Figure 4. 1
Chromatographic retention times of select peptides, showing consistency of RT
and adjacency of sample fractions from which they were identified.
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Supplemental Figure 4. 2
Scatter plot of experimental and predicted RTs of peptides from experimental
batch 2 - 7. up = number of unique peptides trained
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Supplemental Figure 4. 3
Functional analysis of biomarkers for enriched cellular components
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Supplemental Figure 4. 4
Normalized peak areas of CNDH2_HUMAN condensin subunit, superimposed
with CDS1-SCHPO against increasing concentrations of its heavy-labeled stable
isotope standards spiked into a background matrix of plasma.
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Supplemental Figure 4. 5
Flowchart of PRM method development
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Supplemental Figure 4. 6
Differential abundance analysis of validated proteins, showing changes across
the three sample collection time points: baseline, post-bypass (P-BP) and postoperative day one (PO1). †: SAA1 and SAA2 could not be distinguished in the
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validation phase as none of the peptides unique to them met the quantification
criteria.
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Chapter Five: Conclusions and Future Directions

Conclusions
This series of works contribute to the growing body of evidence regarding the
possibility of discovering and using diagnostic biomarkers to diagnose delirium.
We systematically reviewed recent published literature that provided a birds-eye
view of untargeted, discovery proteomic experiments for biomarkers of delirium.
We then demonstrated that the use of a targeted strategy for the purposes of
discovery, however powerful this approach may be, can lead to misleading
conclusions because of the unavoidably biased nature of targeted approaches.
We subsequently applied the biomarker pipeline to plasma samples from our
study cohort, and comprehensively profiled them for proteomics signatures of
delirium. Summarized below are the major conclusions drawn from this thematic
body of evidence.
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Systematic review of proteomic contributions to delirium biomarker research
The list of potential candidate biomarkers identified in eight studies that met the
study criteria suggest that a panel of proteins, rather than a single biomarker,
would allow for discriminating delirium cases from non-cases. With a total of eight
hypothesis generating studies over the last demi-decade, delirium biomarker
research may be at its very early stages. Although functional analyses of the
identified biomarker pool are consistent with the prevailing mechanistic
hypothesis of neuroinflammation, a systems-biology view of delirium
pathomechanisms has yet to fully emerge.

Perioperative Hyperoxia and Delirium after Cardiopulmonary Bypass
In our cohort of patients, peri-operative hyperoxia treatment was found to have
no associations with long-term neurocognition at one-year post-operative.
However, analysis for the impact on the immediate post-operative neurocognitive
function reveals that peri-operative hyperoxia significantly contributes to the
occurrence of post-operative neurocognitive dysfunction. Targeted
measurements of four markers of neuroinflammation, despite their known
associations with delirium in published literature, showed no associations with
the outcome of delirium nor contributed any mediating role in the occurrence of
delirium. Taken together, (1) our data suggests that the association between
intra-operative oxygen treatment and neurocognitive function is one of a dose-
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response-time relationship; and (2) use of targeted strategies for the purposes of
discovery defies fundamental principles of biomarker discovery.

Intraoperative Plasma Proteomic Changes in Cardiac Surgery
Comparative analyses of proteomic profiles between delirium cases and noncases revealed 16 biomarkers as signatures of cardiopulmonary bypass, and 11
as potential diagnostic candidates of delirium. While many of the identified
biomarkers are non-specific markers of inflammation, novel identifications such
as serum amyloid A1 (SAA1) and A2 (SAA2), pepsinogen A3 (PEPA3) and
cathepsin B (CATB) shed new lights on delirium. Briefly, extra-hepatic production
of SAA1 and SAA2 in the brain hints the possibility of brain-specific biomarkers of
delirium. PEPA3, a native protease in the human stomach, found in significantly
higher concentrations in the plasma of delirium cases suggest a break in the
gastric mucosal integrity. This observation is consistent with an increased vagal
tone as the body activates the cholinergic anti-inflammatory reflex in response to
the physiological stress from cardiac surgery and CPB. Lastly, differential
abundance of CATB, a well-known biomarker of Alzheimer’s disease with a
strong correlation, among delirium cases suggest that delirium and AD may have
a common pathophysiological starting point. Equally important in this study is the
potential of mass spectrometry close the time gap in translational biomarker
research by eliminating the bottlenecks of biomarker verification and validation.
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Future Directions
Validation in a larger independent cohort
Although biomarker validation outlines in Chapter Four was performed on an
independent set of samples, it is severely underpowered. It is in our research
interest to conduct a carefully designed validation experiment on discovered
biomarkers, using samples from a larger independent cohort of patients.

Animal Models for Delirium Biomarker Research
Although most original biomarker studies at the moment are done with clinical
samples, very few studies have attempted to study delirium in animal models.
One notable study by Wang, Velagapudi [139] used older APPSwDI/mNos2-/- AD
mice (CVN-AD) that underwent orthopedic surgery. Findings from this study was
instrumental in advancing our understanding of the role of the neurovascular unit
and the blood brain barrier in the pathogenesis of delirium. In this study, authors
ascertained that the immune systems of the experimental mice were naïve. While
animal models are simpler and relatively more controllable, with possibly less
noise in acquired data, they also present with significant challenges. A major one
is the correlation between cognitive assessments in humans (e.g., with the use of
the confusion assessment method) and that used for animals. For animal studies
to enhance our understanding of delirium, future approaches will require
cognitive tests that assess specific brain functions similar to that being tested in
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the humans, and for human studies to evaluate for the baseline immune or
inflammatory state of subjects before recruitment into studies.

Number of scans relative of proteins identifications from plasma and the possible
role of post-translational modifications
Our study focused on global proteomic changes in plasma. As a result, posttranslational modifications and how they relate to the occurrence of delirium were
not studied. Throughout our experiments, we observed that only a small fraction
of MS2 scans provided meaningful proteomic information. Given that native
plasma proteases likely modify proteins in ways that are largely unknown, and
the role of PTM in the pathogenesis of delirium is only now emerging, this is an
interesting question for future research in this space.

Multi-omics approach to diagnostic biomarkers of delirium
The growing body of evidence regarding delirium biomarkers underscores the
complexity in identify definitive molecular signatures of delirium. In addition to
proteomic approaches, many scholars have also attempted biomarker discovery
at the gene, transcript and metabolite levels, all of which significantly contributes
to our understanding of delirium pathomechanisms. It is likely that the different
omic approaches only offer partial insights about the condition and when taken
together, may offer a more complete molecular view of delirium. Interestingly,
differentially abundant biomarkers such as SAA1 and APOA4 among other
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plasma proteins, that functionally interact with lipoproteins suggest that lipidomics
may also play a role in the pathomechanism of delirium. Taken together, a multiomics approach may offer a more complete understanding of the molecular
underpinnings of delirium.

Statistical tools for longitudinal proteomics data
Statistical analyses for longitudinal proteomics data, especially those with
repeated measures is largely unexplored. When analysis required the
comparison of dimensions in the same dataset (for example pre- versus postsurgery and cases versus controls), published literature is inconsistent on the
right approach to analyses. While some authors have suggested the use of
difference of the differences, others have used the overlap of features after
performing comparison on the two dimensions separately. Yet some authors
have also suggested regression modeling and the use of spectral count and
other MS-centric information for variance estimation in such modeling. As
proteomic biomarker research grows with the advent of modern mass analyzers,
this warrants statistical method development that is tailored to the specific
context of MS-derived data.
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Chapter Six: Additional Works and Contributions

Affinity-based profiling of endogenous phosphoprotein phosphatases by mass
spectrometry
Brooke L. Brauer, Kwame Wiredu, Sierra Mitchell, Greg B. Moorhead, Scott A.
Gerber, Arminja N. Kettenbach
https://doi.org/10.1038/s41596-021-00604-3

Abstract
Phosphoprotein phosphatases (PPPs) execute >90% of serine/threonine
dephosphorylation in cells and tissues. While the role of PPPs in cell biology and
diseases such as cancer, cardiac hypertrophy and Alzheimer’s disease is well
established, the molecular mechanisms governing and governed by PPPs still
await discovery. Here we describe a chemical proteomic strategy, phosphatase
inhibitor beads and mass spectrometry (PIB-MS), that enables the identification
and quantification of PPPs and their posttranslational modifications in as little as
12 h. Using a specific but nonselective PPP inhibitor immobilized on beads, PIBMS enables the efficient affinity-capture, identification and quantification of
endogenous PPPs and associated proteins (‘PPPome’) from cells and tissues.
PIB-MS captures functional, endogenous PPP subunit interactions and enables
discovery of new binding partners. It performs PPP enrichment without
exogenous expression of tagged proteins or specific antibodies. Because PPPs
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are among the most conserved proteins across evolution, PIB-MS can be
employed in any cell line, tissue or organism.

Contribution
KW contributed to study conceptualization and revision of manuscript
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Development and validation of inducible protein degradation and quantitative
phosphoproteomics to identify kinase-substrate relationships
Rufus Hards, Charles L. Howarth, Kwame Wiredu, Ian LaCroix, Juan Mercado
del Valle, Mark Adamo, Arminja N. Kettenbach, Andrew J. Holland, and Scott A.
Gerber
https://doi.org/10.1101/2021.12.08.471812

Abstract
Phosphorylation signaling is an essential post-translational regulatory
mechanism that governs almost all eukaryotic biological processes and is
controlled by an interplay between protein kinases and phosphatases.
Knowledge of direct substrates of kinases provides evidence of mechanisms that
relate activity to biological function. Linking kinases to their protein substrates
can be achieved by inhibiting or reducing kinase activity and quantitative
comparisons of phosphoproteomes in the presence and absence of kinase
activity. Unfortunately, most of the human kinases lack chemical inhibitors with
selectivity required to unambiguously assign protein substrates to their respective
kinases. Here, we develop and validate a chemical proteomics strategy for
linking kinase activities to protein substrates via targeted protein degradation and
quantitative phosphoproteomics and applied it to the well-studied, essential
mitotic regulator polo-like kinase 1 (Plk1). We leveraged the Tir1/auxin system to
engineer HeLa cells with endogenously homozygous auxin-inducible degron
(AID)-Plk1). We HeLa cells and determined the impact of AID-tagging on Plk1
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activity, localization, protein interactors, and substrate motifs. Using quantitative
proteomics, we show that of over 8,000 proteins quantified, auxin addition was
highly selective for degrading AID-Plk1 in mitotic cells. Comparison of
phosphoproteome changes in response to chemical Plk1 inhibition to auxininduced degradation revealed a striking degree of correlation. Finally, we
explored basal protein turnover as a potential basis for clonal differences in
auxin-induced degradation rates for AID-Plk1 cells. Taken together, our work
provides a roadmap for the application of AID technology as a general strategy
for the kinome-wide discovery of kinase-substrate relationships.

Contribution
KW contributed to comparative proteomic analyses between fast-degrading
23R3, and slow-degrading B12-11 cell lines. This involved use of unsupervised
dimensionality reduction to explore inherent data structures and zstandardization to eliminate cell-line differences and allow for comparison of the
rates of degradation at the global level and for specific proteins.
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Quantitative survey research in anesthesiology: a field guide to interpretation
Hedwig Schroeck, Kwame Wiredu, Tae Wuk Ko, David Record, Brenda Sirovich
http://dx.doi.org/10.1136/rapm-2020-101299

Abstract
Background Survey research, indispensable for assessing subjective outcomes
in anesthesiology, can nonetheless be challenging to undertake and interpret.
Objective To present a user-friendly guide for the appraisal of survey-derived
evidence, and to apply it to published survey research in the anesthesia
literature.
Methods Synthesizing published expert guidance regarding methodology and
reporting, we discuss five essential criteria (with subcomponents) for evaluating
survey research: (1) relevance of survey outcome to research objective, (2)
trustworthiness of the instrument (testing/validation, availability), (3) collecting
information well (sampling, administration), (4) representativeness (response
rate), and (5) guidance towards interpretation of survey findings (generalizability,
interpretation of numerical outcomes). These criteria were subsequently applied
by two independent assessors to original research articles reporting survey
findings, published in the five highest impact general anesthesia journals
(‘Anaesthesia’, ‘Anesthesia & Analgesia’, ‘Anesthesiology’, ‘British Journal of
Anaesthesia’ and ‘European Journal of Anaesthesiology’) between July 01, 2016,
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and December 31, 2017, which were identified using a prespecified PubMed
search strategy.
Results Among 1107 original articles published, we identified 97 reporting survey
research either employing novel survey instruments (58%), established surveys
(30%), or sets of single-item scores (12%). The extent to which reader-oriented
benchmarks were achieved varied by component and between survey types.
Results were particularly mixed for validation (mentioned for 41% of novel and
86% of established surveys) and discussion of generalizability (59% of novel
survey reports, 45% of established surveys, and 17% of sets of single-item
scores).
Conclusion Survey research is not uncommon in anesthesiology, frequently
employs novel survey instruments, and demonstrates mixed results in terms of
transparency and interpretability. We provide readers with a practical framework
for critical interpretation of survey-derived outcomes.

Contribution
KW contributed to study designing, assisted in database search and literature
screening, analyzed data and contributed to writing manuscript.
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Brachial Artery Embolectomy in a Polytrauma Patient: A Case Report
Kwame Wiredu MBChB, Okyere Isaac BSc MBChB FGCS FWACS
https://www.jce.ro/article/brachial-artery-embolectomy-in-a-polytrauma-patient-acase-report/
Abstract
Introduction: The upper extremity is a frequent site of injury. Upper limb arterial
thromboembolism, a rare complication of such injuries, may be missed if typical
signs, such as pain, pulselessness, and sensory loss, cannot be ascertained or
are overlooked by physicians, especially in the case of polytrauma or comatose
patients. Case presentation: In this report, we present the case of a left brachial
artery thromboembolism in a polytrauma patient for which brachial artery
embolectomy was performed. Before surgery, the diagnosis was established with
doppler ultrasonography of the upper limb vessels, performed upon suspicion of
thrombus formation. Brachial artery arteriotomy and thrombo-embolectomy were
performed using a size 6 Fr Fogarty catheter, after which 500 IU heparin was
flushed to ensure adequate back and forward flow. Limb function and blood flow
were restored immediately after the procedure. Conclusion: A high index of
suspicion, timely assessment, and a prompt intervention can significantly reduce
the rate of limb ischemia and/or amputations in polytrauma patients, especially in
resource-limited settings.
Contribution
KW assisted in delivery of anesthesia to the patient, and collected all relevant clinical
notes from the multi-disciplines to draft manuscript
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